University of Denver

Digital Commons @ DU
Electronic Theses and Dissertations

Graduate Studies

1-1-2011

Hepatitis C Virus-Induced Hepatocellular Carcinoma: Cancer Stem
Cell and Gene Therapy
Heba Samir Esmaeil Allam
University of Denver

Follow this and additional works at: https://digitalcommons.du.edu/etd
Part of the Biology Commons

Recommended Citation
Allam, Heba Samir Esmaeil, "Hepatitis C Virus-Induced Hepatocellular Carcinoma: Cancer Stem Cell and
Gene Therapy" (2011). Electronic Theses and Dissertations. 746.
https://digitalcommons.du.edu/etd/746

This Dissertation is brought to you for free and open access by the Graduate Studies at Digital Commons @ DU. It
has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital
Commons @ DU. For more information, please contact jennifer.cox@du.edu,dig-commons@du.edu.

Hepatitis C Virus-Induced Hepatocellular Carcinoma: cancer stem cell and gene therapy
__________

A Dissertation
Presented to the
Faculty of Natural Sciences and Mathematics
University of Denver

__________

In Partial Fulfillment
of the Requirements for the Degree
Doctor of Philosophy

__________

by
Heba S. Allam
June 2011
Advisor: Dr. Naushad Ali

Author: Heba S. Allam
Title: Hepatitis C Virus-Induced Hepatocellular Carcinoma: cancer stem cell and
gene therapy
Advisor: Dr. Naushad Ali
Degree Date: June 2011
Abstract

Hepatitis C virus (HCV) is an important human pathogen that causes chronic
hepatitis cirrhosis, steatosis and hepatocellular carcinoma (HCC) worldwide. Although
current FDA-approved drugs are partially effective in the treatment of HCV, methods for
cure and vaccine against the virus are still awaited. My thesis work presented here is
focused on finding mechanism (s) of HCV-induced hepatocarcinogenesis and devising
novel means to combat the HCV infection.

Herein, we have shown that long-term HCV expression results in the acquisition
of cancer stem-like cells (CSCs) traits in liver derived cell lines. These traits include
enhanced expression of putative stem cell markers DCAMKL-1, Lgr5, CD133 and cMyc. We also showed that HCV replication is severely impaired by siRNA-led depletion
of the microtubule filaments (MTFs)-associated DCAMKL-1. The cholesterol-lowering
drug, fluvastatin, reduces DCAMKL-1 RNA and affects its protein localization on the
microtubule filaments resulting in marked reduction in the viral RNA and protein
abundance. The mouse xenografts, liver biopsy and tissue microarrays unveiled
overexpression of DCAMKL-1 during chronic HCV infection and cirrhosis, and in the
HCV-replicon expressing cells. We further demonstrate that HCV results in excessive
expression of a-fetoprotein, cytokeratin-19, c-Myc, and c-Src, and activation of b-catenin
pathway in the absence of Wnt ligand. The result presented here implicates a novel
ii

cellular internal ribosome entry site (IRES) element in the c-Src mRNA responsible for
the overexpression of c-Src proto-oncogene under stressed conditions such as HCV
infection.

These results presented here collectively suggest that HCV exhibits ability to
induce reprogramming and/or retrodifferentiation of the host cells and further revealed a
novel HCV-(DCAMKL-1)-MTF-CSCs axis that might be responsible for the HCV RNA
abundance in the infected cells and HCV-induced hepatocarcinogenesis. The putative
stem cell marker, DCAMKL-1, represents a novel cellular target for combating HCV and
liver cancer. The concept of a ‘virus-induced stem cell traits’ can also be extrapolated to
study diseases caused by other RNA viruses.
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Chapter One: Hepatitis C Virus (HCV): a silent epidemic

1. My exploration in the world of tiny microbes
Viruses are fascinating organic macromolecular complexes that exist as obligate
parasites and exhibit high degree of adaptability in their hosts. Although these infectious
agents have caused enormous loss to humans and non-humans equally for centuries, they
also have taught us about the secrets of life, death and diseases. In fact, the viruses have
shaped various life forms on our planet by shuffling and redistributing genes among
organisms. Relatively easy manipulation of their genome offers opportunity for the
investigators to engineer novel means for combating multitude of diseases including
cancer.

Hepatitis C virus (HCV) is one of the highly ‘evolved’ viruses that have clearly
challenged modern human intelligence by posing major health problems worldwide
including my country (Egypt) in terms of both mortality and morbidity. Recent estimates
have shown astounding healthcare spending in USA; rising from $627 million to $6.9
billion (a 10-fold increase) for HCV monoinfection and $63 million to $655 million for
HCV-HIV co-infection during last decade. These reasons made me to believe that my
medical background combined with extensive research may contribute to alleviate human
sufferings due to HCV infection. In this quest, I joined Dr. Naushad Ali’s laboratory who
had published numerous papers on molecular mechanism of translation and replication of
1

HCV. Here, I began working on how HCV survives in human liver for decades without
integrating into the host genome, and how its long-term persistence induces cirrhosis and
liver cancer (hepatocellular carcinoma). To begin with, I will put my efforts in this
chapter to update existing knowledge on the HCV life-cycle, and the advances made in
the field of diagnosis, prevention and treatment for hepatitis C. The next 3 chapters
(Chapters 2-4) are dedicated to describe my research efforts, important findings during
my thesis work, and their implications in designing new treatment strategies against HCV
and liver cancer.

2. Historical Perspective of Hepatitis

In the late 1960's, two hepatitis viruses, hepatitis A virus (HAV) and hepatitis B
virus (HBV) that caused infectious jaundice, were known and were distinguished on the
basis of transmission route and reactivity of patient’s serum to their respective antigens
(Fig 1a).

During early 1970's, transfusion recipients were being screened with the

concept that hepatitis B would be the culprit for transfusion-associated hepatitis, but
neither hepatitis A nor B viruses were found to be responsible. Another hepatitis agent,
hepatitis D virus (HDV) was although identified, it was found to be a defective virus that
is always associated and dependent on HBV infection (Manns 2000).
Extensive epidemiological studies from around the world found a history of
chronic HBV persistence (over 6 months) in 5% of the infected individual. Intriguingly,
over 50% patients with blood transfusion-associated hepatitis exhibited chronic diseases.
These observations led to the search for non-A non-B hepatitis agent in these cases.
Using molecular biological approach during late 1989, a new RNA virus, named hepatitis
2

C virus (HCV) was discovered at Chiron Corporation (USA) as a causative agent for the
parentrally transmitted NANB hepatitis cases (Choo et al 1992). With the development of
RT-PCR and ELISA tests, it was quickly apparent that over 80% of HCV infected
individuals develop chronic hepatitis(Guobuzaite et al 2008). Follow-up over 20 years
and perspective studies showed that many infected persons developed progressive liver
fibrosis, often extending to cirrhosis and/or liver cancer. The long-term studies on natural
history has been proven to be challenging as the disease onset is often subclinical and
progression is extremely slow (Farci et al 1991). Due to these reasons, hepatitis C is also
termed as a ’silent killer’ diseases.

The enterically transmitted NANB hepatitis was later found to be caused by a
calicivirus-like agent termed hepatitis E virus (HEV). Similar to HAV, HEV usually
causes self-limiting acute hepatitis during sporadic infection or outbreaks in the
developing countries. However, higher mortality rate (~20%) among HEV patients due to
fulminant hepatitis has been reported for pregnant women than other hepatitis viruses
(Jilani et al 2007) . Recent studies also indicate that HEV exposure to pregnant women is
extremely high (85%) in the Nile Delta region of Egypt (Stoszek et al 2006). It is
interesting to note that human HEV strains are close relatives of swine and other animal
HEV strains. The zoonotic HEV transmission has been reported in Japan and USA due
to raw meat consumption, it is likely that animal HEV will adapt to infect humans in
future (Renou et al 2007).

3

3. Epidemiology

HCV belongs to the family Flaviviridae and is the only member of the
Hepacivirus genus. The virus is transmitted through direct contact with the blood or body
fluids of infected individuals. (Lavanchy 2011, Martins et al 2011).

Hepatitis C is recognized by the World Health Organization (WHO) as a global
health problem (Fig. 1B). An estimated 3% of the world population (approximately 170
million) and 4 million in USA alone have been infected with hepatitis C. In countries
like the United Kingdom, Scandinavia (0.01% to 0.1%), Americas, Western Europe,
Australia, and South Africa (0.2% to 0.5%) the prevalence of HCV infection is low.
Meanwhile, Intermediate prevalence is recorded in Eastern Europe, Mediterranean,
Middle East, and India. Other countries with intermediate prevalence include Brazil,
Eastern Europe, parts of Africa, and Asia. Egypt has a high prevalence of HCV infection
(17% to 26%) besides Hubei, Mongolia, and Pakistan. Among injection drug users
(IDUs), HCV and HIV coinfection is a major problem. HCV is acquired relatively soon
after the intravenous drug use. It is estimated that 50% to 90% of IDUs with HIV also
contract HCV infection. As a result, liver disease from HCV has become the leading
cause of death in the U.S. in persons coinfected with HIV (Gyarmathy and Racz 2011).

4. HCV in Egypt: a case of unintended medical malpractices
One of the highest prevalence rates (10-13%) of HCV infection in the world is
found in Egypt (Fig 1.1B). In certain areas such as delta-Nile region, it may rise up to
40% (Fallahian and Najafi 2011). The epidemic appears to have been initiated during
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vigorous public-health campaigns using intravenous tartar emetic to eradicate a parasitic
infection, schistosomiasis, during 1950s through 1982 (Frank et al 2000). Before 1986,
intravenous tartar emetic was the main schistosomiasis treatment used in Egypt. At that
time, glass syringes and needles were inadequately sterilized by boiling due to time
restraints and limited resources. As a result, these treatment campaigns improved
schistosomiasis-related morbidity but created hepatitis C disease at epidemic proportion
in Egypt. Consequently, a high incidence of hepatic morbidity and mortality from the late
complications of HCV infection has emerged , such as chronic hepatitis, cirrhosis and
hepatocellular carcinoma (HCC) (El-Zayadi et al 2007, Strickland et al 2002). While
HCV has six major genotypes worldwide (Simmonds et al 2005), the most predominant
in Egypt is genotype 4 representing over 90% of cases, with 4a as the dominant subtype .

5. Natural History of HCV

Exposure to infected blood is the main transmission route of HCV including
Blood transfusion especially that was done before 1992 and intravenous drug use. Highrisk sexual activity, organ transplantation from an infected donor, occupational exposure,
hemodialysis, and birth to an infected mother, household exposure and intranasal cocaine
use are other risk factors. According to the Centers for Disease Control and Prevention
(CDC), HCV transmission through transfusion of contaminated blood products is now
approximately 1 in 500,000 to 2,000,000 transfusions due to the mandatory
implementation of HCV screening. High-risk drug (60%) and sexual behaviors (20%)
were the most common risk factors for acute HCV infection in the U.S. from 1991-1995.
10% of infections were attributed to other modes of transmission. In 10% of persons
5

with HCV infection no recognized source of infection can be identified, despite the fact
that most persons in this category are associated with low socioeconomic level(Mellor et
al 1995).
a. Acute hepatitis
As the majority of acutely infected cases are asymptomatic, acute hepatitis C
infection is frequently missed clinically; 70% to 80% of the blood transfusion
documented cases patients were asymptomatic (Chen and Morgan 2006), 20% to 30% of
adults with acute HCV infection may show clinical symptoms. The incubation period
ranges from 3 to 12 weeks after first exposure. Symptoms includes malaise, anorexia,
jaundice and weakness (Czepiel et al 2008). Serum alanine aminotransferase (ALT)
levels, start to rise 2 to 8 weeks after exposure due to hepatocyte necrosis, and can reach
levels up to 10-folds the upper normal limits (Vince 2005). The HCV RNA can be
detected in the serum 1 to 2 weeks after exposure. In some cases (20%), acute hepatitis C
can be self-limited with symptoms lasting several weeks then subside along with ALT
and HCV RNA levels decline. Acute HCV infection severe enough to cause fulminant
liver failure is rare. The patient becomes positive for anti-HCV antibodies with the onset
of symptoms 1 to 3 months after exposure and is detected by enzyme immunoassay. Up
to 30% of patients also show false negative results for anti-HCV at the onset of their
symptoms, making HCV antibody an unreliable test in the diagnosis of acute infection.
Besides, anti-HCV antibody titers can be low or even undetectable in immunodeficient
patients.

6

b. Chronic hepatitis
In Chronic hepatitis C, the viral RNA persists in the blood for at least 6 months
after onset of acute infection. Approximately 75%-85% of infected patients do not clear
the virus after 6 months and chronic hepatitis develops. Factors affecting the rate of
chronic HCV infection includes the age at time of infection, gender, ethnicity, and
jaundice severity during acute infection (Fiel 2010).
c. Extrahepatic manifestations
A number of other extrahepatic manifestations has also been demonstrated with
hepatitis C that include the development of fatty liver (steatosis), autoimmune
phenomena, peripheral neuropathy, sialadenitis, uveitis, corneal ulceration, and
polyarteritis nodosa.(Jacobson et al 2010).

Deposition of circulating immune complexes in small and medium blood vessels
results in the development of a condition known as Essential Mixed Cryoglobulinemia
(EMC). EMC presents with rash, arthralgias, and weakness. It is also reviewed that
hepatitis C can be found in 95% of all patients with EMC (Jacobson et al 2010).
Investigators have concluded that hepatitis C may have a causative role in EMC as AntiHCV antibodies can be detected in the vessel walls of skin biopsy specimens taken from
patients with EMC and chronic vasculitis. Furthermore, Interferon (IFN) therapy has
been shown to lead to symptomatic improvement of both rash and joint pains. However,
symptoms almost reappear upon cessation of therapy (Pietrogrande et al 2011). Described
in several reports, the increased incidence of Non-Hodgkin B-cell lymphoma occurs in
patients with hepatitis C.

7

Figure 1.1 Viral hepatitis and worldwide impact. A. Types of hepatitis viruses and
clinical outcomes of the infections. The arrows with red color show clinical outcomes of
HCV infection B. Prevalence and distribution of HCV worldwide. C. Proposed
mechanism of attachment/entry of the virus to host cells.
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A positive association between HCV and NHL was first described along with
cryoglobulinemia

using

bone

marrow

biopsy(Marcucci

and

Mele

2011).

Glomerulonephritis is also one of the extrahepatic manifestations associated with
hepatitis C infection. Patients are noted to have significant nephrotic range proteinuria
and most cases of glomerulonephritis are also associated with cryoglobulinemia.
Membranoproliferative glomerulonephritis is the most common histologic lesion found in
those patients(Fabrizi et al 2010). Hepatitis C has also been associated with endocrine
disorders including an increased incidence of antithyroid antibodies and diabetes
mellitus. Recently the association has been uncovered between hepatitis C and diabetes
mellitus, and It was demonstrated that among individuals older than 40 years, patients
with hepatitis C infection were 3 times or more likely to have type 2 diabetes mellitus
than those without hepatitis C infection.(Maheshwari and Thuluvath 2011). Also Several
dermatologic disorders have been described in association with hepatitis C. These include
porphyria cutanea tarda (PCT) and lichen planus.

d. Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the
world, accounting for approximately one million deaths with an increasing trend of new
incidences annually (Farazi and DePinho 2006) HCC incidence and mortality are
increasing, while mortality from other cirrhosis-related complications appears to be
declining. HCC is also the most prevalent form of primary liver cancer that is
histologically and etiologically distinct from other forms of primary liver cancer. High
mortality associated with this disease is mainly attributed to the failure to diagnose HCC
9

patients at an early stage and a lack of effective therapies for patients with advanced stage
HCC. In the US and Europe, the rise in incidence is mainly due to the current HCV
epidemic and is expected to continue to increase over the next two decades (Marrero and
Pelletier 2006).

HCC has a multifactorial etiology, with affecting disease course and prognosis. In
most patients (Approximately 70%–90%) with HCC, cirrhosis is a common feature which
develops after long periods of chronic liver disease that leads to increased fibrous tissue
and destruction of liver cells, eventuallly allowing tumor development. The risk factors
for developing HCC include HBV and HCV infection with an incidence of 54.4% and
31.1% of liver cancer cases globally, respectively, NAFLD, nonalcoholic steatohepatitis
(NASH), alcoholic liver disease, intake of aflatoxin-contaminated food, diabetes, obesity,
and some hereditary conditions such as hemochromatosis, and some metabolic disorders.
The presence of multiple components appears to further drive the hepatocarcinogenic
process (Yang and Roberts 2010b).

Cirrhosis due to HBV and HCV infection is the major risk factor for developing
HCC. Cirrhosis facilitates the development of cancerous nodules (Caillot et al 2009).
Since liver cirrhosis has a central role in the morbidity and mortality associated with
HCC, establishing the presence and severity of cirrhosis is essential in all patients to
assess prognosis and proceed with the treatment .

There are several oncogenic pathways involved in HCC like phosphoinositol-3kinase/Akt, myc, Wnt/β-catenin, c-Met, and hedgehog (El-Serag and Rudolph 2007,
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Monga 2009). Some of these pathways are developmental pathways, indicating that
some HCCs may arise from liver stem cells. Presence of liver cirrhosis and the resultant
growth inhibition can activate and transform liver stem cells, and according to the work
done by (Lee et al, 2006) there is an evidence suggesting that a stem-cell gene-expression
signature exists in a subset of human HCCs (Lee et al 2006c).

e. HCV as a major risk factor for the development of Hepatocellular
Carcinoma

The main reasons for the increasing incidence of HCC in the developed world are
chronic HCV infection and Non-Alcoholic fatty liver disease (NAFLD) (Regimbeau et al
2004). Chronic Infection with hepatitis C virus (HCV) is considered to be a prominent
epigenetic factor for the development of HCC in most patients. Until now, Direct
evidence for an HCV carcinogenic role is lacking. In the work done by (Velosa et al,
2011), they showed that in compensated HCV-related cirrhosis, sustained virological
response (SVR) due to Interferon alpha treatment markedly reduces the risk of HCC and
improves patients ‘survival (Velosa et al 2011).

In contrast to HBV infection in which, HCC can occur in the absence of cirrhosis
due to viral integration into host DNA, HCV will not be incorporated into the cellular
genome. It induces the development of cancer cells, which proliferate out of control
through different mechanisms including the effect of some proteins of the virus which
may induce the oncogenic process. Furthermore, It has been also proposed that the virus
acquires its oncogenic effect via oxidative stress, and by activation of different oncogenic
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signal pathways. The studies done by (Fishman et al, 2009)(Fishman et al 2009) and (Hu
et al, 2009)(Hu et al 2009) showed that Differences were found in HCV core gene
sequences between HCC patients and patients with early-stage liver disease with and
without cirrhosis. Other factors may have a role in the development of liver carcinoma
besides the virus determined factors, like the host reaction, the deficient tumor cell
eliminating capacity may also be a factor (Szalay 2010).

Due to the fact that most HCV-related HCC occurs on top of severe fibrosis or
cirrhosis it is also proposed that the mechanism of carcinogenesis is possibly indirect, in
such way that tissue damage, regeneration and repair are required, rather than a direct
viral oncogenic effect or the viral induced inflammatory response (Nash et al 2010). In a
study done by marshal et al 2005, It was shown that hepatocytes from patients with
chronic HCV infection are arrested in G1 and can undergo replicative senescence,
predisposing to malignancy(Marshall et al 2005).

Since chronic HCV infection is a dominant risk factor for the development of
HCC, understanding the molecular basis of HCV-induced CSC-like properties in hepatic
cells will advance our ability to prevent and treat HCC. In adult liver, hepatic
stem/progenitor cells (HSPCs) predominantly reside in bile duct (canal of Herring).
These cells are quiescent with a low proliferating rate and are activated only when the
mature epithelial cells of the liver are continuously damaged or lost. In severe acute or
chronic injury, proliferation and self-renewal of HSPCs are significantly enhanced.
Although HCV is a noncytopathic virus, the infection causes loss of hepatocytes and
significant reduction in regenerative capacity of the liver that ultimately results in
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cirrhosis. These observations clearly indicate that during long-term HCV infectious
process, the normal function of liver stem/progenitor cells are lost or impaired.

Telomere length and chromosomal stability in proliferating cells such as
hepatocytes are maintained in part by telomerase. Shortening of telomere is therefore
thought to reduce the regenerative capacity of organs during aging and chronic disease
limiting proliferation. In the study done by Wiemann et al, 2002 (Wiemann et al 2002), it
was shown that of in a cirrhotic liver, telomeres are significantly shorter than in a
noncirrhotic one, and this shortening is correlating with fibrosis progression. Therefore,
telomere dysfunction and alterations in the micro- and macro environment that stimulate
cellular proliferation

has been proved

to affect development of HCC. Therefore,

reduction in hepatocyte proliferation is thought to enhance cancer formation in cirrhotic
livers. This observation was further supported by an experiment in a rat model in which
hepatocyte proliferation was inhibited by chemicals and carcinogen-induced liver tumor
formation was accelerated (van Gijssel et al 1997). Cirrhosis also activates stellate cells
leading to an increase in the production of growth factors, cytokines, and oxidative stress
products (Bataller and Brenner 2005) which all have been shown to affect hepatocyte
proliferation and so could have a role in tumor formation (El-Serag and Rudolph 2007).
Activation of Akt signaling In liver cirrhosis can promote tumor formation by
suppressing transforming growth factor (TGF)-β–induced apoptosis. Activation of this
pathway has also been linked to activation of β-catenin signaling, further supporting the
hepatocarcinogenic process (El-Serag and Rudolph 2007).
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In addition to all mentioned factors that contributes to the development of HCC,
the molecular alterations occurring in checkpoints that control DNA damage like the p53
tumor suppressor gene and inactivation of the p27 cell cycle regulator have been
described, which may have a role in promoting tumor formation in the cirrhotic
liver(Matsuda 2008).

6. HCV Genotypes and quasispecies

The high spontaneous mutational rate that is characteristic of many RNA viruses
results in a considerable heterogeneity throughout the HCV genome. The 5′ and 3′ UTRs
are the most highly conserved regions of the genome; and the most variable are the
envelope regions (E1 and E2). Genetic heterogeneity has been classified under two
headings: genotype and quasispecies. Genotype represents the genetic heterogeneity of
the virus between patients, and Quasispecies represent the genetic heterogeneity of the
HCV population within an individual patient (Klenerman et al 2000).

Hepatitis C virus has highly related but meanwhile distinct six genotypes, and
various subtypes with different geographic distribution and complex nomenclature. Since
The C, NS 3 and NS 4 domains are the most highly conserved regions of the genome,
these proteins are used as capture antigens for broadly reactive tests for antibodies to
HCV (Zuckerman et al 2001). HCV genotyping system based on PCR of the core region
with genotype specific PCR primers for determination of HCV genotypes 1a, 1b, 2a, 2b,
3a, 3b, 4, 5a, and 6a were developed(Ohno et al 1997).
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The second component of HCV genetic heterogeneity are the quasispecies.
Quasispecies are heterogeneous sequences of the HCV genome within a single infected
person that result from mutations during viral replication. The rate of nucleotide changes
varies significantly among the different genomic regions, with an overall mutation rate of
0.144% to 0.192% nucleotide changes per year. The highest proportion of mutations has
been found in the E1 and E2 regions at both the nucleotide (1.2%–3.4%) and the amino
acid (1.4%–2.7%) levels, particularly in the hypervariable region (HVR) at the amino
terminal end of E2 (Farci et al 2000). Even though this region represents only a minor
part of the E2/NS1 region, it accounts for approximately 50% of the nucleotide changes
and 60% of the amino acid substitutions within the envelope region. Recent studies have
shown that the rate of mutations within the HVR may be accelerated by interferon
therapy (Enomoto et al 1995).The quasispecies nature of HCV may be one of the
mechanisms by which the virus escapes immune responses. Furthermore, strain-specific
viral factors, not distinguishable on the basis of genotype, may play a significant role in
disease severity, thereby potentially explaining different courses of disease.

7. Diagnosis of HCV

There are two types of tests used in the diagnosis HCV infection. Those include
serologic assays that detect hepatitis C virus specific antibodies (anti-HCV) in patients
serum and molecular assays that detect viral RNA.
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a. Serological tests

Screening using HCV Enzyme immunoassay (EIA) to detect HCV antibodies is
routinely done for all blood donors or persons at risk of contracting the disease. The two
enzyme immunoassays (EIAs) approved by the U.S. Food and Drug Administration
(FDA) for clinical use, are Abbott HCV EIA 2.0 (Abbott Laboratories, Abbott Park, IL)
and ORTHO HCV Version 3.0 ELISA (Ortho-Clinical Diagnostics, Raritan, NJ).
Another enhanced chemiluminescence immunoassay (CIA) is VITROS Anti-HCV assay,
(Ortho-Clinical Diagnostics, Raritan, NJ). IF The EIA test for HCV antibody is positive,
additional testing with recombinant immunoblot assay (RIBA) is done to confirm the
diagnosis (Ghany et al 2009, Puoti et al 2009).

b. Molecular tests

Several commercial assays either qualitative or quantitative are available for the
detection of HCV RNA. Because HCV antibodies takes several weeks to develop, EIA
results could come falsely negative in recently infected individuals. PCR can detect HCV
RNA in patient’s serum within 7 to 21 days after exposure and can be used to confirm the
diagnosis and also to monitor the patient’s treatment response. Recently, because of the
highly sensitive real time polymerase chain reaction (PCR)-based assays and
transcription-mediated amplification (TMA) assays that can detect as low as 10-50
IU/mL, monitoring patient’s response during therapy became easier.

In certain situations when patients can not produce anti-HCV antibody, HCV
RNA testing is required especially in immunosuppressed or immunoincompetent patients
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who underwent organ transplant, are on dialysis, are taking corticosteroids, or have
agammaglobulinemia . Similarly, the anti-HCV may represent a false-positive reaction
due to previous HCV infection, or another liver condition like alcoholism, autoimmunity
or iron overload (Hemochromatosis). HCV RNA testing in these situations has a
confirmative role (Scott and Gretch 2007). Because the patient response to anti-HCV
therapies available differ by and is directly related to the viral genotype, genotyping
Assays are employed to determine the appropriate therapeutic approach and required
duration of therapy (Scott and Gretch 2007).

c. Liver biopsy

It is crucial to grade the liver disease in patients with hepatitis C to help guide
treatment. The role of serum aminotransferase levels, HCV viral load, and hepatitis C
genotype is negligible in predicting underlying liver histology. Therefore, it is
recommended in the initial evaluation of all hepatitis C patients that liver biopsy to be
performed to provide Information that can help exclude other causes of liver disease,
determine the rate of progression of disease, and help in monitoring therapies if the
patient is experiencing significant adverse effects. Usually persons infected with
genotypes 2 and 3 respond well to standard therapy, and treatment can be started without
liver biopsy in those patients. The extent of necroinflammatory activity, fibrosis or the
presence of cirrhosis are important determinants whether treatment can be effective or
not, and also gives an idea about malignant transformation possibility in patients with
advanced cirrhosis (Kleiner 2005).
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8. Molecular Biology of HCV

The viral structural proteins are encoded by the N-terminal part of the ORF,
whereas the nonstructural proteins are coded for by the remaining portion of the ORF
(fig.1.2a). Sequence motif-conserved RNA protease-helicase and RNA-dependant RNA
polymerase (RdRp) are found at similar locations in the polyproteins of all of the
Flaviviridae. In addition, all Flaviviridae share similar polyprotein hydropathic profile,
with flaviviruses and hepaciviruses being closer to each other than to pestiviruses. The
ORF is flanked in 5′ and 3′ by untranslated regions (UTR) of 95–555 and 114–624 nt in
length, respectively, which play an important role in polyprotein translation and RNA
replication (Brass et al 2006, Lindenbach and Rice 2005).

The virion contains a positive strand RNA genome encoding a single polyprotein
of 3010 aa.

The polyprotein is cleaved by cellular and viral proteases into structural

(core, and envelope glycoproteins E1 and E2) and nonstructural proteins (p7, NS2, NS3,
NS4A, NS4B, NS5A and NS5B) (Fig.1.2b). Translation of the polyprotein is mediated
by a unique internal ribosome entry site (IRES) that consists of almost the entire 5’
noncoding region and a few nt of the downstream of the initiator AUG codon.

a. Attachment and entry of HCV into cells

The primary target for HCV replication is the liver hepatocytes . HCV E2 attach
with high affinity to CD81 external loop (Fig.1.1C). The low density lipoprotein receptor
(LDLR) and scavenger receptor class B type I (SR-BI) have been proposed as
components of a putative HCV receptor complex. CD81 is a member of the tetraspanin
18

protein family that interacts with EWI-2; A cleavage product of which was recently
reported to inhibit HCV entry by reducing the association of E1–E2 with CD81(Schuster
and Baumert 2009). This cleavage product was not found in hepatocytes, leading to the
suggestion that its expression may explain their inability to support HCV entry in various
non-permissive cell types. CD81 can also associate with Claudin-1 in a cholesteroldependent manner forming complexes that is essential for HCV entry (Meertens et al
2008). Recent Studies supported the idea that lipoproteins play an important role for viral
cell entry (Regeard et al 2008). In addition association to high density lipoprotein (HDL)
enhanced SR-BI guided cell entry which may be due to protection of viral particles from
neutralizing antibodies (Helle and Dubuisson 2008, von Hahn and Rice 2008).

CD81, Claudin-1 and SR-BI expression in normal and HCV-infected human
livers is limited to the basolateral–sinusoidal hepatocellular surface (Jia et al 2008) that
also contains CD81–Claudin-1 complexes. In addition, CD81 is expressed mainly at the
basolateral surface and is excluded from tight junctions with CD81–Claudin-1 complexes
formed at the same surface. Concluded from that, HCV enters the liver through the
sinusoidal blood, to come into direct contact with the basally expressed

receptor

complexes (Reynolds et al 2008). Following attachment The virion envelope fuses with
cellular membranes delivering the nucleocapsid to the cytoplasm. After entry of the viral
genome, translation occurs in the cytoplasm producing a precursor polyprotein, which is
then cleaved by both cellular and viral proteases into structural and nonstructural
proteins. The virus forms a replication complex which is associated with cellular
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Figure 1.2. Genomic organization of HCV and polyprotein processing scheme. A. The
5’NCR, a single, open reading frame that encodes 3010 aa precursor polypeptide and its
processing by cellular and viral protease into individual proteins are shown. ARF,
alternate reading frame protein B. Structure of the 5’NCR. Four structural domains (IIV), polypyrimidine (Py) motifs, multiple AUGs and pseudoknot structure (PK) are
shown. SI and SII are stems of the PK. Translation of the ORF starts at AUG342. C.
Base pairing of miR-122 at two sites within Domain I of the ‘NCR are shown (adapted
from You et al. 2011. Proc. Nat. Acad. Sci. USA 108:3101-3102).
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membranes. Replication occurs in the cytoplasm by the synthesis of full-length negativestrand RNA intermediates that act as a template for viral RNA synthesis. Assembly of
Progeny virions follows by formation of cytoplasmic vesicles that buds through
intracellular membranes and Finally, mature virions are released extracellularly by
exocytosis (Stamataki et al 2008).

b. Molecular mechanism of HCV protein synthesis: a unique internal
ribosome entry site/segment (IRES)

Hepatitis C virus (HCV) polyprotein translation is mediated by an internal
ribosome entry site (IRES) (Wang et al 1995) . A 330 nt, located in the 5′ untranslated
region (UTR) of the genome, controls translation by a mechanism distinct from other
canonical mRNAs. In eukaryotic mRNA The 5′ 7meG-cap structure first assembles with
eukaryotic initiation factor 4F (eIF4F). Subsequently, a 43S ribosomal complex,
composed of the 40S subunit, eIF3, ternary complex (eIF2·Met-tRNAiMet·GTP), and
other factors, binds to eIF4F at the 5′ end and then scans the 5′ UTR of the mRNA in an
ATP-dependent manner until the AUG is positioned the in the ribosomal start site to form
the 48S complex. Subsequent GTP-dependent release of initiation factors and 60S
subunit joining , followed by first peptide bond formation, complete initiation of
translation (Otto and Puglisi 2004).

HCV IRES-mediated translation initiation is independent of the 5′ cap structure or
ATP-dependent scanning and requires only a subset of the canonical initiation factors.
The HCV IRES direct internal initiation by recruiting translation initiation complexes
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directly to the AUG start codon without scanning. Pestova et al.,1998 demonstrated by
Reconstitution of IRES initiation that the IRES assembles on purified 40S subunits
devoid of initiation factors (Pestova et al 1998). This IRES·40S binary complex is formed
near the AUG start codon. The AUG docks in the ribosomal start site after addition of
only eIF3 and ternary complex yielding a 48S complex without eIF4F during the first
step of translation.(Pisarev et al 2005) The HCV sequence and secondary structure are
highly conserved among viral isolates. Based upon phylogenetic comparison to the
related pestiviruses and GB virus-B, the predicted IRES secondary structure was
constructed using chemical and enzymatic probing and mutagenesis (Zhao and Wimmer
2001). The IRES motifs structures of the HCV, pestivirus, and GB virus-B are similar
with regions of conserved sequences. Some sequence differences exists, but the main
structural and functional elements are conserved in all HCV-like IRESs, with the same
mechanism of initiation.

The HCV 5′NTR has four structural domains, designated I to IV. The most
complex is domain III is, having a pseudoknot, multiple helices, and hairpin domains
IIIa–IIIf. Domains IIIa–IIIc and IIIe–IIIf form four-way helical junctions, folding of
which is dependent on physiological concentrations of divalent metal ions (Melcher et al,
2007)(Melcher et al 2003). This secondary structure and atomic details of IRES
architecture was confirmed by computed three-dimensional structures of IRES domains
(Kieft et al 2002, Lukavsky 2009).

The Role of these different IRES domains functions during initiation is not fully
understood but likely involves regulation of initiation complex assembly. The recruitment
22

of the translation initiation complexes is mediated by HCV IRES Domain III with its
basal portion binding with high affinity to the 40S subunit (Kieft et al 2002), and also
contacting ribosomal proteins involved in the binding and positioning of mRNA and
tRNA(Otto et al 2002). The apical portion of domain III (IIIb) interacts with eIF3
involved in mediating ternary complex stability and subunit assembly (reviewed in
(Merrick 2000). Domain II interacts with ribosomal protein S5 protruding into the
ribosomal start site, leading to a conformational change in the 40S subunit, suggesting
roles in both mRNA and tRNA regulation (Fletcher et al 2002). Domain IV controls
Proper positioning of the initiation codon.

Several factors influence the Activity of the HCV IRES. Most important is the Xtail at the 3’ end of the HCV genome that appears to enhance IRES-dependent translation
by an unknown mechanism (Ito and Lai 1997). Some cellular factors have been
demonstrated to bind to the HCV IRES stimulating translation. These cellular factors
include polypyrimidine- tract-binding protein (PTB) (Ali and Siddiqui 1995), the La
antigen (Ali and Siddiqui 1997), and heterogeneous nuclear ribonucleoprotein L(Hahm et
al 1998).

c. 3′ UTR

The 3′ UTR contains approximately 225 nt organized in three regions including a
variable region of approximately 30–40 nt, a long poly(U)-poly(U/UC) tract, and a highly
conserved 3′-terminal stretch of 98 nt (3′ X region) that includes three stem-loop
structures SL1, SL2 and SL3. The 3′ UTR interacts with the NS5B RdRp and with two of
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the four stable stem-loop structures located at the 3′ end of the NS5B-coding sequence.
The 3′ X region and the 52 upstream nt of the poly(U/C) tract were found to be essential
for RNA replication, whereas the remaining sequence of the 3′ UTR appears to enhance
viral replication(Tellinghuisen et al 2007).

d. Viral proteins and their functions

The HCV core protein forms the viral capsid and is composed of an N-terminal
RNA-binding domain I (DI), a hydrophobic central domain (DII) that supports the
association with lipid droplets (LDs), and the C-terminal domain that serves as signal
sequence for E1 (Boulant et al 2006). In addition two variant forms of core protein have
been described (Eng et al 2009). These core variants are not required for viral replication,
but it is unknown yet if they contribute to pathogenesis.
The envelope proteins (E1 and E2) are heavily glycosylated type I transmembrane
proteins with E1 maturation requiring the coexpression of E2. E1 and E2 form
noncovalently linked heterodimers forming a receptor on the surface of the HCV particle
(Lindenbach and Rice 2005). The p7 protein act as an ion channel known as viroporin
and is required for HCV assembly and release. The NS2 protein does not have a direct
role in viral replication, but is required for the production of infectious virus particles
(Tellinghuisen et al 2007).

HCV genome encodes four viral enzymes; NS2-3 autoprotease and NS3-4A
serine protease, NS3 helicase and NS5B RNA-dependent RNA polymerase, all of which
are essential for HCV replication and infectivity (Chevaliez and Pawlotsky 2006).
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Inhibiting the activity of NS3 serine protease, stalls the replication of HCV. Therefore,
the NS3 serine protease has become an interesting target for viral therapeutics. NS3 is a
multifunctional protein, with an N-terminal serine protease domain and a C-terminal
RNA helicase/NTPase domain. It cleaves the viral polyprotein at four junctions and its
activity is essential for the generation of components of the viral RNA replication
complex and helps virion assembly. The serine protease domain is a member of the
chymotrypsin serine protease family. NS4A is a small (54-amino-acid) protein that
anchors NS3 to cellular membranes through an N-terminal hydrophobic peptide. The
serine protease domain requires coordination of Zn2+ by three cysteine residues distal
from the active site for Proper folding. In addition, the NS3-4A protease activity has
been implicated in blocking the host cell's ability to mount an innate antiviral response
(Shi and Lai 2006).

The NS4B protein is a membrane protein with a complex structure.
Overexpression of this protein leads to membrane alterations, indicating that it is
probably required for the formation of the membrane-associated viral replication complex
(Brass et al, 2006).(Brass et al 2006) NS4B was also described to bind to viral RNA and
compounds enhancing RNA replication (Glenn 2006). NS5A is another key factor for
RNA replication and assembly expressed in a hyperphosphorylated form, which seems to
be important for production of infectious virions(Tellinghuisen et al 2007).
Hyperphosphorylation of NS5A is suggested to reduce its interaction with the human
vesicle-associated membrane protein-associated protein A ( hVAP-A) which acts as a
vesicle sorting protein, directing nonstructural proteins to lipid rafts (Poenisch and
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Bartenschlager 2010). Several cellular proteins have been described to bind to NS5A.
Cyclophilin A (CypA) is one of those proteins, which has become an important target for
antiviral therapy.

e. Mechanism of HCV Replication

The mature nonstructural proteins and a few cellular proteins forms a membrane
associated replicase complex and initiate replication of the genome at the 3’ end for
synthesis of negative strand RNA, which in turn, serves as a template for producing more
positive strand genome(Tellinghuisen et al 2007). These dynamic processes cause
extensive rearrangements in the intracellular membrane structures and alterations in
signaling pathways in infected cells forming a membrane-associated replication
complex(Lindenbach and Rice 2005). The formation of such a complex is a feature
typical of plus-strand RNA viruses like poliovirus or Flaviviruses(Brass et al 2006) and it
permits the production of viral proteins and RNA in an isolated compartment. As NS4B
is a major component of the viral replication complex and has an RNA-binding activity,
it facilitates attachment of the viral positive strand RNA. After NS5B, the RNAdependent RNA polymerase is recruited by Cyclophilin A, to the viral replication
complex, Replication replication results in negative strand intermediate which is further
used to make the positive strand progeny that incorporates into new virus particles. The
viral helicase unwind newly transcribed positive strand form its template negative strand
and this positive sense strand becomes available for translation, transcription or
packaging in new virions (O'Leary and Davis 2010).
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f. Evasion of immune system by HCV

Viral persistence is attributed to HCV ability to evade the adaptive and innate
components of the host's immune system (Fig.1.3). IFN is a major effector of innate
antiviral immunity and is naturally produced in response to viral infection when viral
pathogen-associated molecular patterns (PAMPs) are recognized as nonself and are
bound by cellular pathogen recognition receptors (PRRs), including Toll-like receptors
(TLRs) and the RIG-I-like receptors (RLRs). Within hepatocytes, RIG-I is a major PRR
of HCV infection wherein PAMP interactions serve to trigger intracellular signaling
cascades in the infected hepatocyte to drive IFN production and the expression of
interferon-stimulated genes (ISGs). ISGs function to limit virus replication, modulate the
immune system, and to suppress virus spread (Guobuzaite et al 2008). The hepatic innate
immune response is triggered when the infected cell recognizes a pathogen-associated
molecular patterns or PAMP within the virus as nonself through the actions of cellular
pathogen recognition receptors or PRRs. PRRs include Toll-like receptors (TLRs),
melanoma differentiation-associated gene 5 (MDA5) and the RIG-I-like receptors
(RLRs). The RLRs have a C-terminal RNA helicase domain that has RNA-binding
activity. Of this family, only RIG-I and MDA5 have N-terminal tandem caspase
activation and recruitment domains (CARDs) that are necessary for RIG-I function and
bind long stable double-stranded RNA ligands different from RIG-I ligands. RIG-I is a
main PRR in HCV infection) (Liu and Gale 2010). The PAMP/PRR interaction triggers
signaling cascades that induce the expression of antiviral effector genes in the infected
hepatocytes driving IFN production which in turn stimulates the the expression of
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interferon-stimulated genes (ISGs) both within the infected cell and non-infected cells
that respond either locally or systemically to the secreted IFN. ISGs are responsible for
inhibiting virus replication, modulating the immune system, and preventing virus spread.
During HCV infection, RIG-I and TLRs signaling

pathways

promote Interferon

regulatory factor- (IRF-) 3 and nuclear factor-kappa B (NF-κB) nuclear translocation and
transactivation functions through its CARDs signaling domain interaction with the
downstream molecule, mitochondria-associated MAVS (also called IPS-1, VISA or
CARDIF) (Loo et al 2008) (Liu and Gale 2010).

The HCV NS3 is a multifunctional helicase/protease protein.

It harbors N-

terminus protease and C-terminus NTPase/RNA helicase domains. The protein plays a
remarkable role in the evasion of host innate immunity in addition to its critical roles in
polyprotein processing and replication. HCV NS3/4A efficiently cleaves two pathogen
associated molecular pattern (PAMP) receptors, RIG-I and IPS-1 (Tasaka et al 2007). In
addition, Replication of HCV RNA causes strong ER stress (Waris et al 2005). Among
the HCV proteins, core, E1 and NS3, NS5A are shown to be potent inducer of reactive
oxygen species (ROS); their expression lead to DNA damage and induction of STAT3
and NFkB (Waris et al 2005);(Waris et al 2002a).

9. Treatment of the HCV infection

Although there are many drugs and HCV protein inhibitors in the pipeline,
pegylated interferon with ribavirin is the only option for effective treatment of a few of
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Figure 1.3. Current model for HCV-resistance and immune invasion
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the HCV strains. However, more than half of the patients do not show sustained viral
clearance. With these drugs (Pereira and Jacobson 2009, Vermehren and Sarrazin 2011).
Many investigators were able to developed vaccines against HCV proteins but these
vaccines have been shown to be ineffective against preventing the viral infection.

The primary goal of therapy in the hepatitis C patient is to achieve a sustained
viral response, which is defined as undetectable HCV RNA 6 months after termination of
antiviral therapy. Second goal is improvement in histologic findings and quality of life
and the prevention of HCC. Patients with persistently abnormal liver enzyme test results,
detectable HCV RNA, and an abnormal liver biopsy result are candidates for antiviral
therapy. Several regimens have been licensed in the United States for the treatment of
chronic hepatitis C. These regimens include IFN-alfa-2a, IFN-alfa-2b, IFN-alfa-con
(consensus)-1, pegylated IFN-alfa-2b, combination IFN-alfa-2b and ribavirin, and
combination pegylated IFN-alfa-2b and ribavirin. Pegylated IFN-alfa-2a alone and in
combination with ribavirin is currently awaiting approval by the US Food and Drug
Administration .

The current FDA-approved standard of care (SOC) for HCV infection consists of
weekly injections of pegylated interferon-α along with twice-daily oral ribavirin (PegIFN/RBV regimen). The sustained viral response (SVR) with this SOC depends on strain
of the virus as well as host attributes such as genetic variations. For example, patients
infected with genotype 1, the SVR rate is generally <50% with 48 weeks SOC treatment
whereas for the HCV genotype 2 and 3, it is between 70-80% (Vermehren and Sarrazin
2011).
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A number of drugs that include the specifically targeted antiviral therapies for
hepatitis C (STAT-Cs), and cellular targets against HCV (CTACs) are at various stages
of clinical trials or have been stopped because of their adverse effects, multiple drug
resistance or ineffectiveness in the patients (Kieffer et al 2010b). The most successful
among STAT-Cs include drugs against NS3 protease/helicase (telaprevir, boceprevir),
NS5B polymerase (nucleoside and non-nucleoside analogues) and NS5A protein (BMS790052).

The use of telaprevir or boceprevir, in combination with Peg-IFN/RBV regimen
was reported to increase the SVR rate by 20% in shorter duration (within 24 weeks) as
compared the SOC alone (48 weeks) in patients infected with HCV genotype 1.
Similarly, impressive potency of NS5A inhibitor (BMS-790052) has been shown in
clinical trial (Gao et al 2010).

With all these successful stories and enthusiasm, cure for the HCV infection has
been elusive not only because of adverse effects on patients but also due to emergence of
drug-resistance (Fridell et al 2010, Kieffer et al 2010b, Liu et al 2009, Pockros 2010).
Anemia (up to 37% with telaprevir and up to 56% with boceprevir), skin problems for
telaprevir (rash and pruritis) and dysgeusia for boceprevir in addition to the influenza-like
symptoms, cytopenias and depression caused by the SOC are major hindrance in
successful treatment.

The viral variants with reduced susceptibility to STAT-Cs occur naturally at low
levels due to error-prone HCV replication mechanism, and can be selected in patients not
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responding to STAT-C/SOC treatment. Susceptibility of HCV against these drugs
diminishes due to gradual incorporation of mutations in the virus that have been
demonstrated during in vitro and in vivo testing. These drugs have huge potential for
misuse due to prescribing physician’s poor understanding of the therapeutic populations,
inadequate viral-assay testing, poor side-effect management, and lack of monitoring for
antiviral resistance (Thompson and McHutchison 2009, Toyoda et al 2010).

Statins are well tolerated by patients with HCV and may be added in standard
therapy as a cellular target for anti HCV (CTAC) therapy. More recently, Himmelbach et
al. (Himmelsbach et al 2009) demonstrated that Sorafenib, an FDA and EU approved
drug for the treatment of HCC also inhibits HCV replication in cell culture. Sorafenib has
been shown as a potent inhibitor of c-Raf that interacts with the HCV NS5A. The CTAC
inhibitors (e.g. NIM811, Debio 025) for the HCV protein-interacting partners such as
cyclophilins A and B are also in clinical trials. However, due to adaptive mutations in the
HCV proteins, the drug-resistance is inevitable as reported in a number of studies (Yang
et al 2008).

HCV induced stem cell-like features may contribute to the long-term persistence
of HCV and HCV-induced aggressive HCC. Therefore, new CTAC inhibitors whose
potencies are not compromised by the HCV adaptation and drug cocktail with diverse
mechanisms of action are needed to combat HCV infection. Such multi-dimensional
approach is likely to be effective against both the HCV and the HCV-led initiation of
liver carcinogenesis.
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10. Models used for investigation of HCV infectious processes

Humans and Chimpanzees are the only known natural host of HCV. However,
over three decades, investigators have tried to develop various models to study HCV
infection and replication process.

The most important ones that contributed in

understanding the viral infection are as described below:

a.

HCV replicons

The HCV replicons were constructed from cDNA isolated from the liver of
subjects chronically infected with a genotype 1b strain and consisted of the HCV 5' NTR
and the genes coding for the capsid protein fused in-frame with the selectable marker
gene, neomycin phosphotransferase (Neo), which upon expression confers resistance to
the cytotoxic drug G418 and ending with HCV 3' NTR HCV 3' NTR. (Figure.1.4) The
IRES element from encephalomyocarditis virus (EMCV), drives translation of the HCV
non-structural proteins (Blight et al, 2006) (Blight and Norgard 2006) . Huh-7 cells
transfected with transcripts synthesized in vitro and selection with G418 enabled isolation
of a low number of surviving cell colonies.

Many improvements to the replicon system allowing the establishment of
transient replication assays for other HCV genotypes eg. 1a, 1b, and 2a have been made.
The identification of adaptive mutations that enhance HCV (huh 7.5) led to the
development of replication competent full-length genomes. More recently, the HCV
subgenomic replicons cell tropism has been expanded to non-hepatoma cell lines and
mouse hepatocytes. Recently, the identification of genotype 2a-derived replicons
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efficiently replicating in cell culture needless of adaptive mutations has enabled the
development of systems supporting the complete virus life cycle (Ashfaq et al 2011).

b. Chimpanzee

As the only animal model available, the chimpanzee has been commonly used to
study mechanisms of acute and chronic HCV infection and these studies have greatly
contributed to the current understanding of HCV infection, including immunity and
pathogenesis (Bukh 2004). However, there are many drawbacks in the chimpanzee model
that limit its use. First of all, HCV-infected chimpanzees rarely develop chronic liver
disease to the same extent seen in HCV-infected humans (Hiraga et al 2007), making the
chimpanzee not an ideal model for studying the mechanisms of HCV pathogenesis.
Moreover, chimpanzees are expensive, difficult to handle, and need special housing and
care in appropriate non-human primate research facilities. These limitations of the
chimpanzee model have stimulated progress toward developing alternative animal
models for HCV research.

c. Mouse models

Due to its limited permissiveness in animals, HCV was only studied in humans or
in chimpanzees. Recently, a new chimeric mouse model was developed to be permissive
for HBV and HCV infection. The new mouse model, uPA+/+-SCID represent mice with
a transgene-induced liver disease. Mice are transplanted with primary human hepatocytes
early after birth. These human hepatocytes were able to integrate in the parenchyma and
progressively repopulate the diseased mouse liver with all their normal metabolic
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functions preserved. The successfully transplanted mice were then infected with HCV
(Barth et al 2008). This model will allow in vivo expression of HCV proteins and provide
an important tool for understanding virus–host interactions, and pathogenesis of HCV
infection as many of these mouse models exhibit aspects of HCV-related liver disease.
They also will help

studies to evaluate the

safety and efficacy of new antiviral

compounds against HCV.

d. JFH1 infectious clone

Studying many aspects of the hepatitis C virus (HCV) life cycle could not be
reproduced in cell culture. This obstacle has slowed research and hampered progress on
the development of effective antivirals and vaccines against HCV. Recently, Robust
production of infectious HCV in cell culture has been achieved using a unique genotype
2a strain HCV genome derived from the blood of a Japanese patient with fulminant
hepatitis C (JFH-1) (Berke and Moradpour 2005, Cai et al 2005, Wakita et al 2005).
Moreover, the virus particles generated from the JFH-1 clone(fig.1.4) proved to be
infectious in vivo both in chimpanzees and in chimeric mice containing transplanted
human liver populations (Lindenbach et al 2006, Wakita et al 2005). By introducing
multiple adaptive mutations this infectious HCV genotype 1 could also be produced and
maintained in cell culture and The full-length JFH-1 RNA was transfected into Huh7
cells. Subsequently, viral RNA efficiently replicated in transfected cells producing nearly
10(5) infectious units per milliliter within 48 hours and viral particles were secreted and
was able to infect naive Huh7 cells (Zeisel and Baumert 2006).
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11. Hypotheses and Aims

While maintaining their phenotypes by self-renewal process, the cancer stem-like
cells (CSCs) function as seed elements of the solid tumors including hepatocellular
carcinoma. Because HCV is a dominant risk factor for the HCC development and HCCs
contain cells with stem cell gene-expression signatures (discussed above), we
hypothesize that long-term infection of HCV causes phenotypic changes. These changes
might be due to altered expression of oncogenes and cancer stem cell markers. Keeping
in view of the above-described problems, my thesis work was focused on three major
specific aims:
i.

To investigate if HCV-expressing cells undergo phenotypic changes and
exhibit enhanced expression of oncogenes (e.g. c-Src) and putative cancer
stem cell markers

ii.

To investigate possible mechanism of the HCV-induced hepatocarcinogenesis

iii.

To develop novel means for targeting marker (s) that control abundance of the
HCV genome
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Figure 1.4. JFH1 RNA represents genotype 2, isolated from a Japanese patient with
severe acute hepatitis (Wakita et al 2005) and is currently being used as infectious
model. The second model is the subgenomic replicon system in which the sequence from
core through NS2 is replaced with neomycin resistance gene followed by
encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES). The HCV IRES
translates Neomycin phosphotransferase (Neor) gene that confers resistance to G418 drug
in tissue culture. The EMCV IRES translates NS3-NS5B that are required for the viral
replication. The replicon expresses NS5A-GFP chimeric protein. Using this model, we
have studied mechanism of viral replication, and function of viral and cellular proteins on
the HCV life-cycle. proteins’ Huh-7 or Huh7.5 cells transfected with the replicon
synthesized in vitro and selection with G418 enabled isolation of a replicon expressing
cells.
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12. Conclusion

HCV is one of the most important human pathogens. Its global presence and
severity of the liver diseases have proven to be detrimental. Likewise, its economic
burden is huge. The research activities in academic institutions and pharmaceutical
laboratories have been focused for years on the development of novel therapeutic agents
for hepatitis C. The HCV field has taken a giant leap during last ten years by advancing
HCV culture methods, unraveling molecular mechanism of HCV entry and infectious
processes, and by developing new classes of HCV inhibitors.

However, these

developments are not enough to fully understand HCV pathogenesis. Furthermore, owing
to its quasispecies nature due to its high mutation rate, viral resistance is a major issue for
vaccine and drug development. Till now, current treatment approaches are not curative.
While HCV on its own is a huge medical problem, the association between HCV
infection and hepatocellular carcinoma is an added insult to the injury.

The work presented in this thesis provides a novel concept of HCV virology by
delineating relationship between HCV infectious process and development of cancer stem
cell-like traits in the host cells. Using RNA interference for targeting a putative stem cell
marker (DCAMKL-1), which is known to be involved in colon and pancreatic cancer,
this work has set a precedent that delivery of DCAMKL-1 antagonist by gene therapy
technology or by small molecule inhibitors will help in reducing the risk of HCV-induced
liver carcinogenesis.
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Chapter Two: Hepatitis C Virus-Induced Cancer Stem Cell-like Signatures

1.

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common malignancy
worldwide, accounting for approximately one million deaths annually (Farazi and
DePinho 2006, Parkin 2001, Yang and Roberts 2010a). The high mortality associated
with HCC is attributed to the failure of early stage diagnosis and lack of effective
treatment for patients with advanced stage HCC (Farazi and DePinho 2006, Woo et al
2010, Wu et al 1996). Chronic infection with hepatitis C virus (HCV) is considered to be
a prominent risk factor for the development of HCC (Bartosch et al 2009, Levrero 2006,
Wurmbach et al 2007). More than 170 million people (>4 million in USA alone) are
infected and HCV-related liver disease is increasing globally. Although a strong
relationship between HCV-induced chronic liver disease and development of HCC is
widely accepted, the molecular mechanism of HCV-induced hepatocarcinogenesis is not
clearly understood.

HCV is a positive strand RNA virus classified as a hepacivirus of the family
Flaviviridae (Moradpour et al 2007, Poenisch and Bartenschlager 2010). Among the 6
genotypes, 12 subtypes and various quasispecies (Mellor et al 1995), 1a and 1b are the
most prevalent strains in the US and are least responsive to the currently available
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antiviral treatments (Fried et al 2002, Manns et al 2001).

HCV genome (9600 nt)

encodes a single polyprotein that is processed co-translationally into three structural (C,
E1 and E2) and seven nonstructural (NS) polypeptides (p7-NS2-NS3-NS4A-NS4BNS5A-NS5B) (Lindenbach and Rice 2005). Similar to other positive strand RNA viruses,
HCV replicates via synthesis of negative strand RNA using replication complexes (RCs)
comprising most of the NS proteins and yet undefined cellular factors (Bartenschlager et
al 2010, Poenisch and Bartenschlager 2010). The virus employs a remarkable survival
approach by recruiting an abundant liver-specific miR-122 for stability and replication of
its genomic RNA (Jopling et al 2005, Machlin et al 2011). During infection, HCV
induces web-like membranous structures, and uses lipid-raft and microtubule filaments
(MTFs) for its replication and transport (Lai et al 2008, Moradpour et al 2007, Wolk et al
2008). Additionally, the viral NS3/4A protein cleaves retinoid inducible gene-1 (RIG-1)
and mitochondrial antiviral signaling protein (MAVS) to suppress innate immunity (Gale
and Foy 2005, Qu and Lemon 2010, Raychoudhuri et al 2010). It also induces ER stress
and alters a cascade of signal transduction pathways that control cell cycle and cellular
growth and metabolism (Fukasawa 2010, Tardif et al 2005, Waris et al 2002b).

HCV-induced molecular alterations in infected cells significantly contribute to
HCC development and progression. These alterations may include: i) loss of tumor
suppressor proteins; ii) activation of oncoproteins such as c-Myc; iii) activation and
secretion of cytokines such as transforming growth factor TGF-β; and iv) alterations in
the Wnt/ß-catenin signaling leading to nuclear accumulation of β-catenin, which are
found in 33 to 67% of HCC cases (Bartosch et al 2009, Park et al 2009). Activation of β40

catenin is essential for liver development because deletion of the protein in mice results in
fetal death due to impaired liver cell proliferation and increased apoptosis (Thompson
and Monga 2007). The activated β-catenin has been demonstrated in cells located at the
tumor’s invasive front in colon carcinomas (Zulehner et al 2010). The Wnt/ -catenin
signaling pathway is also important for tumor progression because it modulates
differentiation and maintenance of stem cells (Alison 2005, Lee et al 2006a, Zulehner et
al 2010).

CSCs display several key characteristics of normal tissue stem cells such as selfrenewal and unlimited proliferative and differentiation capacity. They also possess the
intrinsic ability to reproduce all aspects of the parent tumor after metastasis (Alison
2005).

Thus, the “hierarchical model of cancer” considers CSCs as tumor “seed

elements”, which are responsible for cancer initiation, re-initiation after metastasis and
local recurrence after therapy (Marquardt et al 2010, Shi et al 2008). Histopathology
study of chronic liver disease and experiments in mice support the existence of CSCs in
HCC (Mishra et al 2009, Shi et al 2008). The origin of CSCs and factors affecting their
fate are still being debated. Recent studies indicate that induction of “stemness” in
normal tissues or abnormal self-renewal,

differentiation and proliferation of

stem/progenitor cells might be key elements in the generation of CSCs (Lowry et al 2008,
Mishra et al 2009).

Multiple transcription factors and signaling pathways, including Wnt/ß catenin,
Notch and Hedgehog, may be involved in the induction and maintenance of “stemness”
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in fully differentiated cells (Thompson and Monga 2007, Yin et al 2010). Induction of
pluripotency/multipotency in adult somatic cells can be carried out by simultaneous
expression of several transcription factors (a set of Oct4, Sox2, Klf4 and c-Myc or Oct4,
Sox2, Lin28 and Nanog) in recipient adult cells using various delivery vehicles such as
viruses, transposons, and bacterial plasmids (Aoi et al 2008, Kaji et al 2009, Park et al
2008). Successful generation of pluripotent stem cells (iPSCs) has been accomplished by
manipulating culture conditions and with limited number of pluripotency factors (Kim et
al 2009). The most widely accepted evidence for pluripotency/multipotency is the
formation of spheroids and teratoma, and unlimited self-renewal of the reprogrammed
cells.

Because HCV replicates in fetal hepatocytes and the presence of CSCs have been
demonstrated in HCC (Alison 2005, Lazaro et al 2007, Mishra et al 2009), It was
essential to investigate whether HCV could induce cancer stem cell-like properties in
liver-derived cells. This study shows that continued HCV expression is linked to the
overexpression of a putative stem cell marker DCAMKL-1 that is used by the replicon
for its efficient replication. Using various cell lines and a tumor xenograft model, the
study further demonstrate that majority of HCV replicon-expressing cells acquire
characteristic of hepatic progenitor cells, and form a distinct tumor phenotype than the
parent cells lacking the replicon. The HCV-related tumors possess CSCs with higher
invasive and metastatic potential than their normal counterparts (negative for HCV).
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2. Materials and Methods

2.1. Antibodies

Antibodies used in this study were purchased as indicated and used in accordance
with the manufacturer’s suggestion: anti- DCAMKL-1, CD133, SOX2, LGR5, CK19,
human serum albumin, α-fetoprotein and HCV NS5B polymerase were purchased from
Abcam; anti- α-tubulin, Lin28B, c-Src, and actin ( Cell Signaling); anti-c-Myc and antiOct3/4 (Santa Cruz Biotechnologies); anti-Lin28 (Protein Tech Group), and anti-Klf4
(Abgent).

2.2. Cell culture and transfection assay

The FCA4 cells are derived from Huh7 hepatoma cell line and replication of a
subgenomic HCV replicon in this cell line has been characterized previously (Ali et al
2002, Guo et al 2001). The GS5 cells are derived from Huh7.5 cell line [interferon curedHuh7 cells negative for the HCV replicon (Blight et al 2002)] and express HCV
subgenomic replicon that encodes NS5A-GFP (Nelson and Tang 2006). These cell lines
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 1x
Pen/Strep, 1x non-essential amino acids and 10% fetal bovine serum (all from
Invitrogen), and maintained at 37°C and 5% CO2. To evaluate effects of microtubule
disruption on HCV replication, Huh7.5 and GS5 cells (each ~ 1x106) were treated with
vinblastine (30 µM) or DMSO (vehicle) for 3, 6, 9, 12 and 24 h. Total lysates of cells

43

were prepared according to the protocol described for Pierce Cell Lysis Kit for Western
blot (M-PER).

The siRNA that targets nt 308-327 (5’GGGAGTGAGAACAATCTAC3’) of both
AS and AL isoforms of DCAMKL-1 mRNAs (siDCAMKL-1) and scrambled siRNA
(SCR) were purchased from Ambion. Incremental amounts of the siDCAMKL-1 or SCR
RNAs (0, 20, 50, 100 nM) were transfected into GS5 cells using SiPORT NeoFX
transfection agent (Applied Biosystems) according to the manufacturer’s protocol.
Similar amounts of transfection reagent alone were used in control transfection. The cells
were harvested 48 hr post-transfection to analyze RNA and protein levels.

2.3. Florescence-activated cell sorting (FACS)

The DCAMKL-1 antibodies were conjugated with Dylight 549 (Thermo Fisher)
using Pierce kit. The conjugated DCAMKL-1 antibodies were purified and allowed to
bind cell surface DCAMKL-1 of Huh7.5 or GS5 cells for 30 minutes at RT as described
(May et al 2008, May et al 2010). The cells were washed twice with autoMACS rinsing
buffer (Miltenyi Biotec), resuspended in the same buffer and sorted using Influx-V Cell
Sorter (Cytopeia, Seattle).

The instrument was calibrated with unstained cells. The

DCAMKL-1-positive and negative cells were collected separately in DMEM and grown
as described above. For spheroid assay, 100 DCAMKL+ or DCAMKL- cells in 2X
DMEM media (50 ul) were mixed with matrigel (50 ul) on ice-bath, plated in nonadherent/ultralow attachment 96-well plates (BD Biosciences, CA). Fifty microliter
media was added on the top of the gel 2 hr later and the cells were grown as described
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above. Two weeks later, 100 ul DMEM were added in each well. The spheroids were
evaluated and photographed under inverted light microscope after 4-5 weeks.

2.4. Real-time reverse transcription-PCR analyses

Total RNAs were isolated from culture cells or tumor xenografts using RNeasy
isolation kit (Qiagen). The RNA samples were subjected to reverse transcription with
Superscript II and random hexanucleotide primers (Invitrogen). In the subsequent step,
the cDNAs were used as templates to perform real-time PCR by SYBR chemistry method
(SYBR® Green I; Molecular Probes). The target (HCV and DCAMKL-1) and control
(actin) RNAs were amplified using Jumpstart Taq DNA polymerase (Sigma) and the
following primers:
Actin: 5’GGTGATCCACATCTGCTGGAA-3’(forward)
and 5’ATCATTGCTCCTCCTCAGGG3’ (reverse);
DCAMKL-1: 5’AGTCTTCCGATTCCGAGTTGAG3’ (forward);
and 5’CAGCAACCAGGAATGTATTGGA3’ (reverse);
HCV: 5’CGGGAGAGCCATAGTGG3’ (forward)
and 5’AGTACCACAAGGCCTTTCG3’ (reverse).
The crossing threshold values assessed by the real-time PCR were evaluated for
the transcripts and normalized with β-actin mRNA. The mRNA levels were expressed as
fold change relative to control with ± SEM value.
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2.5. Tumor Xenografts in mouse model

Athymic nude Balb/c mice were purchased from Jackson Laboratory and housed
in pathogen-free conditions. The animals were treated in accordance with guidelines of
the American Association for Accreditation of Laboratory Animal Care and the Policy on
Human Care and Use of Laboratory Animals. The studies reported here were preapproved and supervised by the Institutional Animal Care and Use Committee (IACUC).
Huh7.5 or GS5 cells (5 × 106) were washed with PBS three times, resuspended in the
same buffer, and injected subcutaneously into the dorsal flanks of 4–6 week old mice (3
mice for each injection). Tumors were measured with calipers and the volumes were
calculated using formula: 0.5 X (length X width2). The tumors were resected 4-6 weeks
after cell transplantation and the portions of the tumors were preserved in 5% formalin
for immunohistochemistry and stored at -800 C in RNase inhibitors for real-time PCR or
directly frozen for Western Blot analyses. The control animals were treated similarly but
injected with same volume of the buffer.

2.6. Immunohistochemistry

Heat-induced epitope retrieval was performed on 4 µm formalin-fixed paraffinembedded sections using a pressurized Decloaking Chamber (Biocare Medical) in citrate
buffer (pH6.0) at 99°C for 18 min. Slides were sequentially treated with 3% hydrogen
peroxide, normal serum and BSA at room temperature for 20 min. After incubation with
primary antibodies and washing with PBS, the slides were incubated in peroxidase-
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conjugated EnVision™+polymer detection kit (DAKO). Slides were developed with
diaminobenzidine (Sigma).

2.7. Immunofluorescence and confocal microscopy

Cells grown on glass cover-slips (VWR) were rinsed briefly in phosphatebuffered saline (PBS), fixed in 4% paraformaldehyde in PBS pH 7.4 for 20 min at room
temperature, washed twice with ice cold PBS and permeabilized in ice-cold acetone.
Cells were incubated with blocking buffer (10% serum, 0.01 % Triton X-100, in PBS, pH
7.4) for 1 hour, washed with PBS and treated with primary antibodies in PBS-T
containing 1% BSA for 1-2 hr at room temperature or overnight at 4°C. After thorough
washing with PBS-T, cover-slips were incubated in appropriate AlexaFluor conjugated
secondary antibodies. The nuclei were counterstained with DAPI (0.1-1 µg/ml PBS).
The cover-slips were mounted on microscope slides in ProLong Gold antifade reagent
(Invitrogen) for detection of Immunofluorescence using Nikon 80i or Leica TCS NT (for
confocal microscopy).

2.8. DCAMKL-1 staining in human liver tissue array

The liver tissue arrays were purchased from US Biomax (Rockville, MD). The
array contains 30 normal and cancer adjacent normal liver tissues, 10 cases of
inflammation with HBV, 9 samples of cirrhosis with HBV, and 31 samples of cirrhosis
without HBV infection. The arrays were subjected to immunohistochemical staining as
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described above using anti-DCAMKL-1 antibodies (ab31704).

The intensity of

DCAMKL-1 were evaluated and plotted on the arbitrary scale of 0-3.

2.9. Induction of human iPS cells

The

minicircle producer

plasmid pMC.BESPX and the E.coli

strain

ZYCY10P3S2T were obtained from Dr. Zhi-Ying Chen, Stanford University School of
Medicine. The ZYCY10P3S2T strain was transformed with pMC.BESPX and grown in
5 ml LB containing Kanamycin (50 ug/ml) at 37°C with shaking at 250 rpm. An
overnight culture were grown by combining 100-ul of the previous culture with 400 ml of
terrific broth (TB) containing Kanamycin (50 ug/ml). On day 2 after 16-18 hours (OD600
reading between 4-5), the minicircle induction mix (400 ml LB, 16 ml 1N NaoH and 400
ul 20% L-arabinose) was combined with the overnight culture and incubated at 32 °C
with shaking at 250 rpm for 5 hours. Bacteria were then pelleted and minicircle isolated
using Qiagen kit according to manufacturer’s protocol with some modifications (double
volumes of P1, P2, and P3 buffers were used. After purification, just the reprogramming
cassette is obtained and bacterial elements were removed.

3. Results

Hepatoma cells harboring HCV replicon express multitude of stem cell-related
proteins and exhibit cancer stem cell-like features. Normal adult hepatocytes are fully
differentiated cells and lack expression of stem cell markers and pluripotency factors
(Mishra et al 2009). However, these cells can be induced to proliferate rapidly after
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partial hepatectomy and can also be reprogrammed into pluripotent cells (Aoi et al 2008).
In This study we investigated the impact of HCV on partial reprogramming or
retrodifferentiation of GS5 cells that are derived from a hepatoma cell line (Huh7.5).
These cells harbor a Geneticin (G418)-selectable subgenomic HCV-1b replicon that
encodes HCV nonstructural proteins NS3 through NS5B, and a functionally active
NS5A-green fluorescent protein (GFP) chimera (Moradpour et al 2004, Nelson and Tang
2006). The cells partially mimic chronic HCV infection in tissue culture conditions due
to sustained expression of the replicon in the presence of G418. The intensity of GFP in
these cells can be used as a surrogate marker for the efficiency of the HCV RNA
replication (Nelson and Tang 2006).

By indirect immunofluorescence microscopy, extensive expression of several
putative stem cell/pluripotency markers (CD133, DCAMKL-1, Lgr5, Sox2, Oct4, Lin28)
and c-Myc oncogene was observed in the GS5 cells that also demonstrated high level of
HCV replicon expression as evidenced by the presence of intense NS5A-GFP (see
Fig.2.1 and Appendix 1). Eccentric staining of DCAMKL-1 was noted in the area where
punctate localization of the HCV replication complexes (RCs) was more intense.
Previous studies have shown that HCV replication complexes associate with
microtubules through NS5A and NS3 proteins and their saltatory movements are fully
dependent on the intact microtubule filaments (Lai et al 2008, Wolk et al 2008). Since
DCAMKL-1 catalyzes polymerization of tubulins into microtubules (Kim et al 2003, Lin
et al 2000), next to be investigated was the possible role(s) of DCAMKL-1 in HCV
replication. The Fig. 2.2A shows relative localization of the RCs (marked by punctate
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GFP) and DCAMKL-1 in the context of microtubules in GS5 cells. The cells with high
HCV expression (indicated by double arrow) showed higher DCAMKL-1 abundance.
Both DCAMKL-1 and the HCV RCs were concentrated in the regions showing intense
staining for microtubule filaments.

In contrast, cells without high HCV expression

showed much lower expression and localized staining of DCAMKL-1 (single arrow).
These observations suggest a relationship between HCV replicon expression and
DCAMKL-1 levels in a subset of GS5 cell line.

3.1. DCAMKL-1-positive GS5 and Huh7.5 cells exhibit cancer stem cell-like
properties

Recent studies from this laboratory (May et al 2008, May et al 2009, May et al
2010) showed that DCAMKL-1-positive cells can be isolated from colon and pancreatic
cancer cell lines using FACS method (May et al 2009), and that isolated DCAMKL-1positive cells formed spheroids in matrigel (BD Biosciences) and displayed CSCs
properties. This established method was used in this study to isolate DCAMKL-1 and
HCV NS5A-GFP double positive cells (HCV+DCAMKL-1+) from GS5 and DCAMKL1+ cells from Huh7.5 cell line. The FACS data presented in Fig. 2.2B (left panel) revealed
relatively higher percentage of DCAMKL-1+ cells in GS5 pool (1.42%) than that of the
Huh7.5 control (0.36%). Both cell-types positive for DCAMKL-1 formed spheroids in
matrigel (with approximately 5-10% efficiency) in 3-4 weeks (middle panel). GS5spheroids demonstrated higher HCV NS5A-GFP expression in the budding areas than the
spheroid body (right panel). The DCAMKL-1 negative pool of these cell lines failed to
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Figure 2.1. Indirect immunoflorescence microscopy for visualization of cells
coexpressing the HCV replicon (indicated by NS5A-GFP, green) and putative
stem/progenitor cell markers or c-Myc (red) in GS5 culture. Blue, nuclear stain. Also see
appendix 1.
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form spheroids under similar conditions. These results indicate that a subpopulation of
GS5 cells co-expressing high levels of HCV replicons and DCAMKL-1 may exhibit
CSCs features.

3.2. Tumors initiated by GS5 cells are distinct from the Huh7.5-derived
tumors in athymic nude mice

Assuming that very high NS5A-GFP expressing cells also have high DCAMKL-1
expression level (Fig. 2.2A), we used FACS to isolate the top 26% of total GS5
population with the highest green florescence intensities (Fig. 2.3A, indicated by R4).
These cells were then expanded in tissue culture and injected into the dorsal flanks of the
nude mice. In parallel, similar numbers of Huh7.5 cells were injected into the control
mice.

Since both cell lines contain DCAMKL-1+ cells to varying extents, the

transplanted cells formed tumors with 50-60% efficiency over a period of 3-4 weeks. An
example of GS5 tumor in one of the mice is shown in Fig. 2.3B (indicated by an arrow).
The resected tumors (example shown in Fig. 2.3C) were phenotypically characterized and
analyzed for the expression of stem cell/pluripotency markers by immunohistochemistry.
A significant number of DCAMKL-1-positive cells were localized in certain areas of
GS5-tumors in which most cells exhibited high level of activated c-Src expression,
indicating that these tumors are highly aggressive and possess metastatic potential (Fig.
3E). Only rare c-Src and DCAMKL-1 expressing cells were observed for the Huh7.5tumors (Fig. 2.3D) whereas neither was detected in control mouse liver preparations (Fig.
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Figure 2.2. Correlation among DCAMKL-1, HCV and CSCs traits in the repliconexpressing cells. (A) Confocal microscopy for localization of HCV NS5A-GFP (green),
DCAMKL-1 (red) and microtubules (magenta) in GS5 cells as indicated. The field shows
two cells as an example; single and double arrows indicate low and high HCV repliconexpressing cells respectively as indicated by the relative GFP intensities. (B) Isolation of
DCAMKL-1-positive cells from Huh7.5 and GS5 cells grown in tissue culture by FACS
method (left panel), and Spheroid assay (right panel) using isolated DCAMKL-1+
(Huh7.5) or GFP+DCAMKL-1+ (GS5) cells. One hundred cells were plated with culture
media containing 50% matrigel in a 96-well plate. The cells were grown in standard
culture conditions and spheroids were photographed after four weeks (a-d).
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Figure 2.3. Characteristics of tumor xenografts developed by GS5 and Huh7.5 cells. (A)
The highest GFP-expressing cells (R4 gated, 26% of total) were isolated by FACS
method, expanded in tissue culture and 5 million cells were injected into the dorsal flank
of a nude SCID mice (in duplicate). In control animals, similar numbers of Huh7.5 cells
were transplanted. (B) An example of GS5 tumor within animal (indicated with an
arrow). (C) Resected tumor from the animal. The tumors developed by Huh7.5 (not
shown) had varying size but usually smaller than that of GS5-tumors (not shown). Costaining of DCAMKL-1 and active c-Src in the tumor tissues of Huh7.5 (D) and GS5 (E)
by immunohistochemical method. Purple, DCAMKL-1; Brown, activate c-Src [pTyr418
c-Src]. (F) Control, section of the mouse (B) liver stained as in (D, E) showing that both
antibodies were not reactive to the animal liver cells.
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2.3F). This in vivo observation complements our preliminary finding that activated c-Src
is highly expressed in GS5 cells grown in laboratory cell cultures. We next compared
expression of a number of stem cell/pluripotency markers in the xenograft tumor tissues
and culture cells which were derived from both the cell lines. The total cell lysates (2030 ug) were subjected to Western blot analysis using specific antibodies against an array
of stem cell-associated markers.

As shown in Fig. 2.4A, the levels of DCAMKL-1, LGR5 and CD133 were
considerably enhanced in GS5 cells as compared to the control cells (Huh7.5). However,
the levels of pluripotency factors (Oct4, Sox2 and Lin28) were similar in both cell-types.
Unlike cultured cells, DCAMKL-1, LGR5 and CD133 expression and that of
pluripotency factors (Lin28, Sox2, Oct4 and c-Myc) in both tumors were similar. During
GS5 cell transplantation, the animals did not receive the replicon selection marker (G418
drug) due to its high cytotoxicity. As a result, GS5-tumors lost the replicon expression
over a 3-4 week period as indicated by the absence of NS5B band in the Western blot
(Fig. 2.4B, control markers). This is consistent with our observation that withdrawal of
G418 from GS5 culture gradually diminishes the HCV expression (see Fig. 2.7, left
panel). These data suggest that despite the gradual HCV decline over a few weeks,
initiated tumors continued to grow in the animals.

Previous reports indicated that immature hepatic progenitor cells such as oval
cells and cholangiocytes in liver express CK19 protein (Aoi et al 2008, Banaudha et al
2010). The protein is also considered a marker for aggressive HCC subtypes. The CK19
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expression in HCC (with or without HCV) correlates with the lower patient survival and
higher rates of tumor recurrence (May et al 2010, Mellor et al 1995). Striking differences
in CK19 expression were observed between the GS5 and Huh7.5 xenografts by
immunohistochemistry (Fig. 2.5). Higher percentages of GS5-tumor cells expressed
CK19 (Fig. 2.5B) whereas rare Huh7.5-tumor cells expressed this protein (Fig. 2.5A).
This difference was confirmed by Western blot analysis using replicon-expressing two
cell lines. The total lysates prepared from cells grown in tissue culture revealed that both
GS5 (Fig. 2.5C, left panel) and FCA4 (Fig. 2.5D) cells expressed much higher levels of
CK19 than their parent cell-types (Huh7.5 and Huh7 cells respectively). This trend was
clearly reflected in the respective tumor xenografts derived from GS5 and Huh7.5 cells.

To induce pluripotency in Human hepatoma cell line Huh7, the minicircle vector,
p2phiC31-LGNSO was transfected into Huh7 cells.

In the minicircle DNA, the

reprogramming cassette is driven by a CMV promoter leading to the expression of
LIN28, GFP, NANONG, SOX2 and OCT4. The reprogramming genes coding regions in
the cassette are linked by 2A protease sequence, so after transfection the expressed
proteins undergo self cleavage by peptide 2A. In parallel, Huh7 cells were also
transfected with BM45 plasmid harboring HCV replicon, controls were empty vector
DNA transfected Huh7 and lipofectamine only. Total lysates analyzed on SDS-PAGE
showed that both LSNGO and BM45 transfected cells (Fig. 2.6C, lanes 3 and 5
respectively) expressed higher levels of CK19 than their parent untransfected Huh7 cells,
mock or empty vector DNA transfected Huh7 cells (Fig. 2.6C lanes 1, 2, 4 respectively).
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Figure 2.4. Relative expression of putative stem cell markers and induced pluripotency
factors in the culture cells (A) and tumor tissues (B) as indicated. Western blot analysis
was carried out with 20 ug of total lysates of the cells (left panel) and their respective
tumors (right panel). Protein bands of stem cell markers (DCAMKL-1, LGR5, and
CD133) and induced-pluripotency (iPSCs) factors (Oct4, Sox2, c-Myc, Lin28) were
detected by the specific antibodies as indicated. The viral NS5B polymerase and actin
were used as controls. (C) Enhanced expression of DCAMKL-1 in an another HCV
replicon-expressing cell line (FCA4) as compared to the parent cells (Huh7)
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Figure 2.5. Unique features of the GS5-tumors. Enhanced expression of CK19 in GS5derived tumors (B) as compare to that of Huh7.5-derived tumors (A).
Immunohistochemical staining (A, B) for CK19 (brown); Blue, nuclear stain. (C)
Western blot of total lysates (30 ug) of tumor xenografts (right panel ) or culture cells
(left panel) of both cell lines probed for CK19. The upper band in the doublet is
considered as full-length Ck19. Actin, loading control. (D) Western blot for CK19
expression in FCA4 cells that express a subgenomic HCV-1b replicon (indicated by the
presence of NS5B) as that of GS5 but lacks GFP.
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Lin28 was much more expressed by LSNGO transfected cells (Fig. 2.6 D lane 3)
compared to control and mock cells (lanes 1 and 2 respectively).

A similar strategy was employed to detect the hepatoblast marker, α-fetoprotein
(AFP), in xenograft tumors and in tissue culture cells. Western blot analyses reiterated
immunohistochemical findings that GS5-tumor or GS5 culture cells expressed AFP at a
much higher level than Huh7.5 controls (Figs 2.7 A, B, and C). Lysates of GS5 tumors
showed much higher relative expression pattern by Western blot than observed by
immunostaining because AFP is secreted extracellularly (Fig. 2.7B vs. 7C, right panel).
These observations suggest that GS5 cells although were originated from Huh7.5 cells,
they maintain a distinct cellular phenotype in culture conditions as well as in tumor
xenografts.
We also observed a number of CK19+AFP+ and CK19+AFP- progenitor-like cells
in the GS5 tumors (Appendix 2a), whereas these cells were rarely seen in the Huh7.5tumors (Appendix 2b). The most likely inference of these observations could be that
high level of chronic HCV replication results in retrodifferentiation of cells leading to
acquisition of hepatic stem/progenitor-like characteristics.

3.4. HCV replication influences activation of ß-catenin

Previous studies have shown that c-Myc and CK19 expression is affected by βcatenin expression (Thompson and Monga 2007, Zulehner et al 2010). The high level of
c-Myc and CK19 expression observed in GS5 cells (Figs.2.4A and 5C) prompted

59

Figure 2.6. HCV replicon and pluripotency factors induce CK19 overexpression in Huh7
cells. (A) Schematic of the reprogramming cassette-expression plasmid. The CMV
promoter-driven synthesis of a single mRNA results in the translation of a polyprotein
that is self-cleaved by 2A peptide sequence into individual Lin28, GFP, Nanog, Sox2 and
Oct4 proteins. (B) Schematic of preparation of ‘Minicircle’ from the vector DNA (A) for
transfection into Huh7 cells. (C) Western blot after transfection of HCV subgenomic
replicon (lane 5), Minicircle (LGNSO, lane 3), and empty vector DNA (lane 4). Lane 1,
untransfected; lane 2, transfection with lipofectamine alone. (D) Western blot showing
much higher expression of Lin28 in LNGSO transfected cells (lane 3) than untransfected
(lane 1) or Lipofectamine alone transfected Huh7 cells (lane 2). (E) Western blot for two
different HCV replicon-expressing cell lines (GS5 and FCA4) in the presence (plus) or
absence (minus) of G418 selection marker. The specific bands of CK19, NS5B and actin
are as indicated.
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Figure 2.7. Expression pattern of hepatoblast marker in the tumor xenografts and parent
culture cells.
Huh7.5-tumor (A) and GS5-tumor (B) were subjected to
immunohistochemistry for staining of a-fetoprotein (AFP, brown). Blue, nuclear stain.
(C) AFP expression in the total lysates (30 ug) of tumor xenografts (right panel ) or
culture cells (left panel) was detected by Western blot. Actin, loading control.

61

us to investigate the status of ß -catenin in response to the HCV replication. The GS5
cells cultured in the presence of G418 support continued high-level replication of the
HCV RNA whereas withdrawal of G418 leads to decline in replicon expression as
evidenced by decreased NS5B level in the cytoplasm (Fig.2.8A, left panel). The NS5B
reduction was accompanied by decline in both total and active nuclear ß-catenin (right
panel). These results clearly suggest that continued HCV replication is required to
maintain activation of the ß-catenin pathway in the absence of external Wnt ligands. We
also observed the presence of active ß -catenin in tumors as expected (Fig. 2.8B).
However, there were no significant differences between the levels of active and total ßcatenin in both tumor types, in consistence with the c-Myc expression profile for both
tumors and cultured cells (Figs. 2.4A and 2.4B).

3.5. DCAMKL-1 is required for the HCV replication

HCV replication complexes associate with microtubule filaments (MTFs) and use
the MTF-tracks for their movement and transport (Lai et al 2008, Roohvand et al 2009,
Wolk et al 2008). Since DCAMKL-1 protein is known to bind, stabilize and polymerize
tubulins into MTFs (Lin et al 2000), we examined the effect of inhibiting DCAMKL-1
expression on HCV replication. The GS5 cells were transfected with scrambled siRNA
(SCR, control) or siRNA against DCAMKL-1 (siDCAMKL-1). This siRNA targets nt
308-327 (the predicted site) in the DCAMKL-1 mRNAs encoding both the AL (long
form) and AS isoforms [short form, ref. (Engels et al 2004)].
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As shown in Fig. 2.9A, siDCAMKL-1 transfection in GS5 cells resulted in the
inhibition (average 75% at 100 nM) of DCAMKL-1 mRNA level whereas the same
concentration of the SCR had minimal effect. The decrease in mRNA was accompanied
by disappearance of the DCAMKL-1 protein in total lysates, suggesting that the siRNA
had effectively inhibited DCAMKL-1 expression (Fig. 2.9B, lanes 3, 4).

The

DCAMKL-1-depletion in these cells also resulted in significant reduction (70-80%) of
both the HCV RNA and NS5B polymerase levels (Fig. 2.9A and 9B, lanes 3, 4). This
effect appears to be specific as the level of another pluripotency marker, Lin28B (Guo et
al 2006), was unaffected by the siDCAMKL-1 treatment (Fig. 2.9B).

The immunosuppressive drug cyclosporine A (CsA) is known to inhibit
cyclophilins (CypA and CypB), which interact with crucial components of the HCV RCs
such as NS5A and NS5B (Watashi et al 2005, Yang et al 2008). CsA downregulates
HCV replication by inhibiting activities of the RCs (Watashi et al 2005, Yang et al 2008).
More often, however, CsA-treatment results in drug-resistance (Liu et al 2009, Puyang et
al 2010). The CsA treatment of GS5 cells effectively inhibited HCV replication (Fig.
2.9C) and diminished level of NS5B in the GS5 lysates (Fig. 2.9D, lanes 3-5).
Interestingly, CsA treatment resulted in a moderate increase in the DCAMKL-1 protein
(Fig. 2.9D, lanes 3-5) without increasing its transcription level (Fig. 2.9C). It has been
reported that CsA activates AKT and suppresses PTEN; both events culminate in the
activation of mTOR complexes (Han et al 2010).
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Figure 2.8. Activation of b-catenin in response to the HCV replication. (A) The
cytoplasmic and nuclear lysates of GS5 cells cultured for 2 weeks in the presence (plus)
or absence (minus) of G418 selection marker were subjected to Western blot using
specific antibodies as indicated. The unphosphorylated form of ß-catenin is shown as
active protein. (B) Total lysates prepared from tumor xenografts were analyzed by
Western blot for total and active b-catenin.
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The activation of AKT/mTOR signaling favors enhanced cap-dependent protein
synthesis and cell survival. These observations imply that even though CsA successfully
inhibits HCV replication during early phase of treatment, enhanced DCAMKL-1 level
may eventually contribute to CsA-resistance. In fact, we noticed a certain level of NS5B
was not affected by the sequential increase in CsA concentrations (1 through 6 ug/ml,
Fig. 2.9D, lanes 3-5).

3.6. HCV incites resistance to MTFs disruption

The anti-neoplastic drug, vinblastine, binds α-tubulin and inhibits microtubule
assembly by preventing addition of new tubulin subunits (Rendine et al 2010). We
evaluated the effect of vinblastine on Huh7.5 and GS5 cells at different time-points. As
shown in Fig. 2.10 B (lower panel), vinblastine treatment caused clear disruption of
MTFs architecture and showed bundling of MTFs within 7 hr in Huh7.5 cells. Most GS5
cells showed similar bundling pattern and inhibition of NS5A-GFP expression.
However, the bundling of MTFs was less evident in cells showing high NS5A-GFP
presence (Fig. 2.10 A, indicated with an arrow). Longer treatment and further kinetic
analysis suggested that nearly all the GS5 cells eventually died within a week. During
MTF bundling, we further noticed that DCAMKL-1 staining in GS5 cells was weak and
the protein appears to be dislodged from the MTF bundles. Control cells treated with
DMSO alone did not show MTF disruption. These results reiterate the study overall
findings that survival of HCV requires DCAMKL-1 and its intact substrates (MTFs).
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Figure 2.9. DCAMKL-1 is required for the HCV replication. (A) siRNA against
DCAMKL-1 (siDCAMKL-1, 50 nM and 100 nM) or scrambled siRNA (SCR, 100 nM)
were transfected into GS5 cells in triplicate. Total RNAs were extracted and subjected to
real-time RT-PCR. The levels of HCV and DCAMKL-1 RNAs were considered one in
untransfected GS5 cells (Cont.). Actin mRNA in each sample was used as internal
control for PCR. (B) Western blot analysis of siRNAs transfected (lanes 2-4) and
untransfected (lane 1) samples as indicated. (C) Real-time PCR was performed for
detection of HCV and DCAMKL-1 RNA levels after treatment with CsA (3 ug/ml).
Control, DMSO vehicle. (D) Effect of CsA on the levels of HCV NS5B polymerase and
DCAMKL-1. The GS5 cells were treated with 1, 3, 6 ug/ml CsA (lanes 3-5). Lanes 1
and 2 represent untreated and DMSO (vehicle) treated samples respectively. Actin,
internal loading control. Each experiment was repeated three times to confirm the results.
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4. Discussion

We have used a proven replicon-based system to study long-term effects of HCV1 on cells, as a chronic infectious model for HCV-1 is not available. We investigated
HCV-induced phenotypic alterations in liver-derived GS5 cells that express a
subgenomic replicon encoding NS3 through NS5B of the HCV genome. The C-terminus
GFP tagged NS5A (NS5A-GFP) expressed from the replicon is efficiently incorporated
into active replication complexes (RCs) and is distributed in a punctuate pattern in the
cytoplasm with higher concentrations localized in the perinuclear regions [Figs. 2.1 and
2.2 (Gosert et al 2003, Moradpour et al 2007, Poenisch and Bartenschlager 2010)]. GFP
intensity correlates with the level of HCV replication in these cells. We demonstrated that
a small subpopulation of intensely bright GFP+ cells contain RCs in the area highly
enriched in DCAMKL-1 and microtubule filaments (MTFs).

In some cases, co-localization of RCs, DCAMKL-1 and MTFs was observed by
confocal microscopy. These observations and subsequent analyses presented in Figs. 2.2,
2.3 and 2.8 support the existence of an HCV-(DCAMKL-1)-MTFs-CSCs axis in GS5
cells. Using both in vitro and in vivo models, our data provided evidence that this
collaboration promotes HCV replication and HCV-induced hepatocarcinogenesis. We
further found that HCV replication results in the induction of putative stem cells/CSCs
markers and activation of ß-catenin, which are required for the maintenance and selfrenewal of
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Figure 2.10. Effects of vinblastin on microtubule filaments and HCV expression. Huh7.5
(B) or GS5 (A) cells were treated with vinblastin (30 uM) for 7 hrs and subjected to
indirect immunoflorescence microscopy using antibodies against α-tubulin. Arrow, a
vinblastin-resistant cell in GS5 population.
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stem/progenitor cells (Lee et al 2009, Zhang et al 2008, Zulehner et al 2010). The
stem/progenitor cells in an adult organ such as liver are considered to be: i) ‘privileged
cells’ in their niches; ii) relatively resistant to apoptosis, and iii) possess longer life-span
than fully differentiated cells. Thus, HCV appears to employ a unique strategy to ensure
its long-term survival in the infected cells simply by directing the cells to exhibit stem
cell-like properties.

Our studies suggest a novel role of DCAMKL-1 in the HCV replication. Higher
expression of DCAMKL-1 in hepatic cells, and its association with MTFs, led to higher
levels of HCV replication suggesting a certain advantage for virus replication. MTFs
represent dynamic, polarized polymers of α- and ß-tubulin heterodimers that undergo
phasic polymerization and depolymerization required for cellular transport and cell
division (Roohvand et al 2009). DCAMKL-1, by virtue of its MTFs polymerizing and
stabilizing activity may provide MT-dependent transport and fast, saltatory movements of
RCs over long distances (Fukasawa 2010, Gale and Foy 2005). By promoting RC
movement, DCAMKL-1 is likely to increase HCV replication efficiency. It may also
compensate for architectural distortion created by HCV-induced membranous web-like
structures in the cells. Roohwand et al. (Roohvand et al 2009) demonstrated that MTFs
dynamic polymerization/depolymerization also affects post-fusion steps of the HCV life
cycle, and that HCV core protein interacts with tubulin thereby enhancing microtubule
polymerization.

The effects of viral proteins on DCAMKL-1 activities and the

DCAMKL1 interaction with viral components are yet to be investigated.
69

Previous studies done by this lab revealed that DCAMKL-1 level is increased
significantly in pancreatic and colon cancers and its knockdown causes marked reduction
in tumor size in a xenograft model (May et al 2009, Roohvand et al 2009). In this study,
we found evidence of higher DCAMKL-1 expression in human patients with liver
cirrhosis than the normal liver tissues (Appendix. B). The cause of DCAMKL-1
overexpression in tumors and its effects on CSCs is not known yet. Our studies presented
here provide HCV as one causative agent for the overexpression of DCAMKL-1. The
DCAMKL-1+ cells from both cell lines (GS5 and Huh7.5 cells) behave like CSCs in
matrigel further reiterating the previous findings.

Therefore, HCV-led induction of

DCAMKL1 in conjunction with enhanced expression of CD133, Lgr5, c-Myc and ßcatenin may directly force the infected cells on the path of developing into CSCs.
However, not all patients living with HCV develop HCC. Studies have shown that HCV
NS5A inhibits apoptosis in infected cells by inhibiting oxidative stress-induced p38
MAPK activation and K+ efflux (Raychoudhuri et al 2010). Similarly, NS3/4A has been
shown to promote hepatocyte survival and liver regeneration by enhancing NFκB
activities and hepatoprotective TNFα (Rendine et al 2010). Thus, other factors may also
play important role during HCV-induced hepatocarcinogenesis.

Similar to many solid tumor cell lines, the hepatoma cells used in these studies are
expected to contain a population of CSCs because of the expression of many putative
stem cell and pluripotency markers (Nakanishi et al 2010). As a result, both GS5 and
Huh7.5 cells were able to form solid tumors in athymic nude mice. We also observed that
both tumors expressed human albumin suggesting that the tumors were derived from the
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transplanted cells and contain mature human hepatocytes. According to the ‘hierarchical
model’ of cancer, the original phenotypes of CSCs represented in culture pool must also
be maintained in their respective tumors due to self-renewal. We validated this
assumption by comparing expression of hepatoblast and hepatic progenitor markers in
culture cells and the tumor xenografts.

Each tumor, indeed, reflected the original

phenotype of the parent culture cells. For example, GS5 cells and its tumor xenografts
exhibited much higher expression of CK19 and AFP than that of Huh7.5 controls by
Western blot. The GS5-tumors also showed a very high population of CK19+AFP(hepatic stem cells), CK19+AFP+ [hepatoblast and transit amplifying cells, ref. (Zhang et
al 2008)]. These HCV-induced stem-like features were clearly absent in Huh7.5 culture
cells and its tumor xenografts. Higher expression of CK19 in an another HCV replicon
expressing cell line (FCA4) than the parent cell line (Huh7) suggests that these properties
are not limited to GS5 cells. The detection of CK19+ oval cells in HCV-positive liver
cirrhosis (Sun et al 2006) and co-expression of CK19 and AFP in hepatic progenitor cells
(Zhao et al 2009) further support our observations. The HCV-induced distinct traits in
culture cells were subsequently maintained in the GS5-tumor tissues even though the
viral gene expression was diminished during later stage of the tumor development.

Tsamandas et al. (Tsamandas et al 2006) demonstrated that hepatic progenitor
cells (HPC) are frequently present in liver tissues of hepatitis C patients and their number
tends to increase as the disease advances to cirrhosis which is a known risk factor for the
HCC initiation. It was further demonstrated that a large group of patients that do not
respond to the standard HCV treatment show higher expression of CK19 and AFP than
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the responders and these proteins can be used as reliable markers for detecting the HPCs
in these patients. Using extensive gene expression profiling of HCC tissues, other
investigators independently reached to the conclusion that HCC originating from HPC or
HPC-like cells express high level of CK19, AFP and certain stem cell signatures (Lee et
al 2006b, Woo et al 2010). While supporting these observations, our in vitro and in vivo
analyses further provide mechanistic insights that high expression and/or coexpression of
CK19 and AFP is, indeed, caused by HCV-induced retrodifferentiation of hepatic cells
leading to acquisition of HPC-like phenotype. These characteristics were universally
detected in different cell lines and tumor model used here (GS5 and FCA4 cell lines,
G418-withdrawl assay, and tumor xenografts). Our studies also revealed that multiple
DCAMKL-1 positive cells were embedded in the areas of active c-Src expression in GS5
tumors (Fig. 2.3E). It is known that c-Src expression and activities are enhanced under
varying stress conditions that favor tumor growth and metastasis (Allam and Ali 2010).
In these aspects, the GS5-tumor traits are reminiscent of HCC with stem cell features
(Ding et al 2004, Lee et al 2006b). Thus, it is conceivable that HCV-induced
reprogramming of liver cells may contribute to both survival of the virus and
hepatocarcinogenesis.

Finally, our studies provide evidence that active ß-catenin accumulates in the
nucleus in response to HCV expression which may explain higher-level c-Myc
expression in GS5 than the controls [also see ref. (Milward et al 2010)]. Active ß-catenin
was also detected in the tumor xenografts. Using human HCC tissue array and murine
liver tumor model, Zulehner et al. (Zulehner et al 2010) demonstrated significant
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correlation between CK19 expression and that of nuclear ß-catenin. It has been further
shown that lack of nuclear β-catenin causes cells to differentiate into mature hepatocytes
whereas its presence induced retrodifferentiation into immature hepatocyte progenitors.
Therefore, our data, in conjunction with published reports, support the concept of HCVinduced reprogramming of the liver-derived cells. Since the replicon used here lacks
NS2 and C, E1 and E2 structural proteins, the impact of these proteins on the ‘cellular
renovation and reprogramming’ by the virus could not be investigated. A long-term,
chronic HCV infection model that produces high titer HCV particles such as improved
version of JFH1 strain-based cell culture (Banaudha et al 2010, Wakita et al 2005) in
normal human hepatocytes will likely to provide additional clues on these aspects.

Although both Huh7.5 and GS5 or Huh7 and FCA4 cells originated from the
same cell line and propagated under similar culture conditions, the long-term HCV
expression (reminiscent to chronic infection) resulted in stable phenotypic changes in
GS5 cells. These acquired alterations were reproduced in the tumor xenografts of GS5,
which conforms the hierarchical model of tumor initiation by CSCs. Thus, it is highly
likely that GS5 pool contains CSCs with features of hepatic stem cells or hepatic/biliary
precursors because of retrodifferentiation and acquisition of stem cell/CSCs and
oncogenic traits (see model proposed in Fig. 2.11). Consequently, the HCV infection per
se including HCV-induced HCCs poses increased threat of resistance to anti-viral and
anti-cancer regimens, recurrence of the infection and/or tumors, and high mortality of
patients (Frank et al 2010, Kieffer et al 2010a). The Huh7.5 cells, on the other hand,
retained their HCC phenotype both in culture and in tumor xenografts as it lacks the
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HCV-induced alterations.

In conclusion, our data provides DCAMKL-1 as a novel

cellular target for combating HCV replication and/or hepatic CSCs. To inhibit,
DCAMKL-1 expression, siDCAMKL-1 (Fig. 2.9) can be delivered to the target cells
using gene therapy approach by constructing an expression vector for the siRNA.
Alternatively, this laboratory has tried delivery of the siDCAMKL-1 using nontoxic
biodegradable nanoparticles (NPs) made of poly(lactide-co-glycolide) [PLGA].

The

successful delivery of siDCAMKL-1 NPs at the site of tumors in mouse xenograt model
led to the reduction in liver and pancreatic tumor size (Suraben et. el 2009).

In

addition, our studies further argue comprehensive evaluations of anti-HCV drugs in the
setting of chronic/long-term infection for their efficacies.

5. Chapter summary

Hepatitis C virus (HCV) infection is a prominent risk factor for the development
of hepatocellular carcinoma (HCC). Similar to most solid tumors, HCCs are believed to
contain poorly differentiated cancer stem-like cells (CSCs) that initiate tumorigenesis and
confer resistance to chemotherapy. This dissertation studies demonstrate that expression
of HCV subgenomic replicon in cultured cells results in acquisition of CSCs traits. These
traits include enhanced expression of DCAMKL-1, Lgr5, CD133 and c-Myc in
conjunction with long-term maintenance of pluripotency factors. The studies also show
that HCV replication is severely impaired by siRNA-led depletion of the microtubuleassociated putative stem cell marker, DCAMKL-1. The DCAMKL-1-positive cells
isolated by fluorescence activated cell-sorting (FACS) form spheroids in matrigel. The
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work further demonstrates that HCV replicon-expressing cells initiate tumors in mice.
The resulting tumors exhibit characteristics of HCCs that are originated from hepatic
progenitor-like cells and are phenotypically distinct from the tumors initiated by parent
cells lacking the replicon.

This phenotype expresses high-levels of α-fetoprotein,

cytokeratin-19 and pluripotency markers. HCV-induced activation of ß-catenin, c-Myc,
and c-Src indicates the aggressive nature of the tumor. These results collectively suggest
that HCV exhibits intrinsic ability to induce retrodifferentiation and CSC signatures, and
DCAMKL-1 represents a novel cellular target for combating HCV and the virus-induced
hepatocarcinogenesis.
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Figure 2.11. Proposed retrodifferentiation model for the HCV-induced liver
carcinogenesis. Solid arrows, pathways of normal hepatic stem cell differentiation;
arrows with broken lines, possible source of Huh7.5- and GS5-derived tumors. Majority
of Huh7.5 culture/tumor cells lack hepatic/biliary precursor markers although these cells
contain stem/progenitor cell traits.
Therefore, they represent intermediate or
differentiated hepatocytes. On the other hand, GS5 culture/tumor cells contain stem
cell/progenitor cell markers, and high population of CK19+AFP- (hepatic stem cells) and
CK19+AFP+ (hepatoblast, transit amplifying cells or hepatic/billiary precursors). The
expression level of CK19 and AFP in these cells are remarkably higher than those of
Huh7.5. These acquired distinctions are likely attributed to retrodifferentiation of the
parent Huh7.5 cells into GS5 phenotype that was induced by sustained expression of the
HCV replicon. HPC, hepatic progenitor cell. (B) Probable consequences of the HCVinduced HPC traits.
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Chapter Three: Targeting DCAMKL-1 with FDA-approved drugs for treatment of
HCV infection

1. Introduction
A number of drugs that include the specifically targeted antiviral therapies for
hepatitis C (STAT-Cs), and cellular targets against HCV (CTACs) are at various stages
of clinical trials or have been stopped because of their adverse effects, multiple drug
resistance or ineffectiveness in the patients (Kieffer et al 2010b). The most successful
among STAT-Cs include drugs against NS3 protease/helicase (telaprevir, boceprevir),
NS5B polymerase (nucleoside and non-nucleoside analogues) and NS5A protein (BMS790052). The use of telaprevir or boceprevir, in combination with Peg-IFN/RBV regimen
was reported to increase the SVR rate by 20% in shorter duration (within 24 weeks) as
compared the SOC alone (48 weeks) in patients infected with HCV genotype 1.
Similarly, impressive potency of NS5A inhibitor (BMS-790052) has been shown in
clinical trial (Gao et al 2010). With all these successful stories and enthusiasm, cure for
the HCV infection has been elusive not only because of adverse effects on patients but
also due to emergence of drug-resistance (Fridell et al 2010, Kieffer et al 2010b, Liu et al
2009, Pockros 2010). Anemia (up to 37% with telaprevir and up to 56% with boceprevir),
skin problems for telaprevir (rash and pruritis) and dysgeusia for boceprevir in addition to
the influenza-like symptoms, cytopenias and depression are additional hindrance for a
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successful treatment. The viral variants with reduced susceptibility to STAT-Cs occur
naturally at low levels due to error-prone HCV replication mechanism, and can be
selected in patients not responding to STAT-C/SOC treatment. Susceptibility of HCV
against these drugs diminishes due to gradual incorporation of mutations in the virus that
have been demonstrated during in vitro and in vivo testing. These drugs have huge
potential for misuse due to prescribing physician’s poor understanding of the therapeutic
populations, inadequate viral-assay testing, poor side-effect management, and lack of
monitoring for antiviral resistance.

Clinical trial by our group (Bader et al 2008) and subsequent studies by others
(Harrison et al 2010, Milazzo and Antinori 2010, Milazzo et al 2010) suggest that certain
statins (fluvastatin, simvastatin, lovastatin, and mevastatin) but not pravastatin show
anti-HCV activities both in experimental models and in patients with hepatitis C. It has
been demonstrated that the FDA-approved doses of fluvastatin are well tolerated by
patients with HCV and the drug can provide aid standard of care therapy (Delang et al
2009). Statins are inhibitors of 3-hydroxyl-3-methylglutaryl coenzyme A (HMG CoA)
reductase, which is a rate-limiting enzyme in cholesterol biosynthesis that catalyzes the
conversion of HMG-CoA to mevalonic acid (Fig. 3.1). These drugs are used for the
treatment of hypercholesterolemia and have been reported to exhibit antiviral activities
against a number of viruses (Gilbert et al 2005). The precise mechanism of the anti-HCV
activity of statins has not yet been defined. Recent studies suggest that the anti-HCV
activity of statins may result from inhibition of geranylgeranylation of cellular proteins
rather than the inhibition of cholesterol synthesis.
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Geranylgeranylation is a

posttranslational modification that covalently attaches geranylgeranyl to various cellular
proteins to facilitate their membrane association. These geranylgeranyl groups are
isoprenoids synthesized in the cholesterol biosynthesis pathway. The HCV genome does
not code a geranylgeranyl protein suggesting that the replication of the HCV needs the
host cell geranylgeranyl pyrophosphate synthesis. More recently, FBL2 has been reported
to be a host target for geranylgeranylation. Geranylgeranylation of FBL2 appears to be
critical for HCV replication because the association between FBL2 and NS5A, an
interaction that is a prerequisite for HCV replication, depends on geranylgeranylation of
FBL2 (Kapadia and Chisari 2005, Wang et al 2005, Ye et al 2003).

Himmelbach et al. (Himmelsbach et al 2009) demonstrated that Sorafenib, an
FDA and EU approved drug for the treatment of HCC also inhibits HCV replication in
cell culture. Sorafenib has been shown as a potent inhibitor of c-Raf that interacts with
the HCV NS5A. The CTAC inhibitors (e.g. NIM811, Debio 025) for the HCV proteininteracting partners such as cyclophilins A and B are also in clinical trials. However, due
to adaptive mutations in the HCV proteins, the drug-resistance is inevitable as reported in
a number of studies (Yang et al 2008). Our studies suggest that HCV induced stem celllike features may contribute to the long-term persistence of HCV and HCV-induced
aggressive HCC. Therefore, new CTAC inhibitors whose potencies are not compromised
by the HCV adaptation and drug cocktail with diverse mechanisms of action are needed
to combat HCV infection. Such multi-dimensional approach as proposed here is likely to
be effective against both the HCV and the HCV-led initiation of liver carcinogenesis.
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Figure 3.1. Possible interactions among HCV, miR-122 and cholesterol biosynthesis
pathway. The statins block the rate-limiting enzyme, HMGCR. The interaction of viral
protein NS5A with geranylgeranylated cellular protein FBL2 and HCV RNA are shown.
NS5A also interacts with lipid droplets and membranes (not shown) CoA, coenzyme A;
PP, pyrophosphate. Presented with minor modification of Figure 3.1 shown in J. Virol.
2010. 84:666-670.

80

2. Materials and Methods

Cell

Culture,

real-time

RT-PCR

analyses,

immunohistochemistry,

immunofluorescence and confocal microscopy were done as described in Materials and
Methods, Chapter 2.

2.1. Culture of normal human hepatocytes (NHH)

Normal human hepatocytes from a donor (16 yr, female, non-smoker, died due to
head trauma) were purchased from BD Biosciences in crypreserved form (Catalog #
454550). The cells were stored in liquid nitrogen until needed.

For confocal and

immunoflorescence microscopy, the cells were cultured/maintained in Hepato-STIM
Hepatocyte Defined Medium (BD Biosciences) supplemented with Epidermal Growth
Factor (10 ng/ml) and 1X antibiotic-antimycotic (Invitrogen) on collagen BD cover slips
(22 mm). The cells were incubated at 37°C and 5% CO2, washed after 72 hrs with PBS,
fixed with formaldehyde and stained with antibodies as described in earlier chapter.
Alternatively, the NHH were also maintained in BD Matrigel 6-well plate in the HepatoSTIM complete media to determine their three-dimensional growth pattern. These NHH
were subjected to H&E staining, immunohistochemistry, and staining for DCAMKL-1
and microtubules.
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2.2. Cell proliferation assay:

MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) was
purchased from Biotum, Inc. and used according to manufacturer recommendations. To
investigate cellular toxicity of fluvastatin, 2×104 cells were plated into 96-well plates in
100 ul regular complete DMEM media. After 24 h, varying concentrations of fluvastatin
were added and the plate kept at 37 C in 5% CO2 for 72 or 94 h. The cells were washed
and fresh media (100 µl) and MTT solution (5 mg/ml in PBS) were added to all wells,
wrapped the plate in aluminum foil and incubated for 3-4 h at 37 C. Two hundred µl of
DMSO was added to each well in order to dissolve the formazan crystals formed as a
result of the MTT reaction. Absorbance with an enzyme-linked immunosorbent assay
(ELISA) plate reader at a test wavelength of 570 nm and a reference wavelength of 630
nm.

3. Results

3.1. Fluvastatin reduces abundance of the HCV RNA and NS5B polymerase
in GS5 cells

Recent studies have shown that statins lower HCV titer in patients (Bader et al
2008). The HCV-specific drugs and/or IFN with certain statins have also been
demonstrated to improve efficacy of the treatment (Delang et al 2009, Harrison et al
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2010). However, mechanism of action of different statins against HCV is not fully
understood.
The HCV subgenomic replicon-expressing GS5 cells were treated with increasing
amounts of FLV. Since DMSO is a solvent for FLV, similar amounts of the
solvent/vehicle alone were used in the control culture. The cultures without any drug or
solvent were considered as positive controls. As shown in Fig. 3.2A, increase in FLV
concentration from 0 to 5.0 uM caused marked decrease in the HCV RNA (black bar).
Further increase of FLV (10 uM) did not show additional reduction of the HCV RNA. In
contrast, DMSO alone did not reduce the HCV RNA level at any of these concentrations
(gray bars). The inhibitory effect of FLV on HCV was also confirmed by Western blot
analysis. The total lysates prepared from untreated and FLV-treated cells revealed that
the expression of NS5B polymerase is significantly reduced at 5 and 10 uM (Fig. 3.2B,
upper panel, lanes 5, 6) as compared to the control (lane 1). This reduction was not
noticed the DMSO treated lysates (lower panel). These results clearly indicate that FLV
considerably inhibits HCV RNA and protein levels.

3.2. Effect of mevalonic acid on FLV-led inhibition of the HCV replicon

Mevalonic acid (Mev) is a product of the enzyme HMG-CoA reductase (HMGR)
and is essential substrate for downstream reactions in the cholesterol biosynthesis
pathway. Therefore, inhibition of HMGR by FLV can be antagonized and cholesterol
biosynthesis pathway can be restored by addition of mevalonic acid in the culture media.
Varying amounts of Mev (5, 10, 15 uM) were added to GS5 culture in the presence of
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FLV (5uM). The control cultures lacked FLV but were supplemented with DMSO and
Mev. The HCV RNA levels in these cells were compared with the untreated culture.
Although, 5 and 10 uM of Mev could not recover the FLV inhibition. However, a modest
expression level of the HCV RNA was restored at 15 uM of Mev (Fig. 3.3A). The
DMSO-treated cells alone or with exogenously added Mev did not affect the HCV RNA
abundance. Next, 5 uM of each FLV, pravastatin (Prav) and rusovasatin (Ruso) were
added in the absence or presence (15 uM) of Mev. Only FLV showed reduction (Fig.
3.3B, lane 2) in the NS5B level as compared to the untreated control (lane 1).
Interestingly, addition of 3-fold molar excess of Mev led to very little recovery of the
NS5B level (lane 3). Addition of Prav and Ruso to the cell culture in the absence or
presence of Mev failed to exhibit reduction in the HCV NS5B level under similar
conditions (lanes 4-7). In similar experiments, we further noticed that the FLV-treated
GS5 cells displayed marked morphological changes with induced cytoplasmic
protrusions (Fig. 3.3C-b), which were partially recovered by Mev treatment (Fig. 3.3Cd). These changes were not observed for DMSO (Fig. 3.3C-c) or pravastatin treatment
(not shown).

Our MTT cell proliferation assay on these cells including ASPC1

(pancreatic cancer cell line) and FCA4 (an HCV replicon expressing Huh7 cell lines)
suggest that the FLV-treated cells are viable during this period (72 hr).
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Figure 3.2. Reduction of the HCV RNA and NS5B polymerase abundance by fluvastatin
treatment in GS5 cells. (A) Real-time RT-PCR for detection of the HCV RNA in DMSO
(control, gray bar) or fluvastatin (FLV) in DMSO (black bar). The cells were treated
with different amounts (0-10 uM in media) of FLV. Same amounts (ul) of the solvent
(DMSO) were added in the control samples. Total RNAs were extracted from the cells
using Qiagen Rneasy Kit for the PCR. (B) Western blot for NS5B in FLV-DMSO
(increasing concentrations from lane 2 through 6) and DMSO alone (Cont.) as indicated.
Actin, loading control.
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3.3. Fluvastatin induces ‘microtubule bundling’ in cancer-related cells but
not in normal human hepatocytes

The morphological changes in GS5 cells due to FLV-treatment (Fig. 3.3C)
prompted us to investigate the status of microtubule filaments (MTFs) using confocal
microscopy. Interestingly, the FLV-treated but not the DMSO-treated GS5 cells exhibited
extensive ‘bundling’ of the microtubule filaments (Fig. 3.4A). The induced skeletal
change was accompanied by the decrease in NS5A-GFP intensities and displacement of
replication complex from the MTF bundles (Fig. 3.4B, lower panel). The MTF bundling
effect was observed in Huh7.5 but was less pronounced (Fig. 3.4C, lower panel). In
contrast, normal human hepatocytes were completely resistant to the FLV-induced MTF
disruption (upper panel).

3.4. Effect of Fluvastatin on DCAMKL1

Because DCAMKL-1 catalyzes polymerization of tubulins into microtubules, we
looked into its cellular localization in the FLV-treated and untreated cells. As shown in
Fig. 3.5, DCAMKL1 localization in GS5 cells was disturbed and dislodged from
microtubules as a result of the bundling effect induced by FLV (lower panel). This
bundling and redistribution of DCAMKL1 did not occur in DMSO treated cells (upper
panel).
The miR-122 has been shown to facilitate the replication of HCV by binding to
the domain I in the HCV 5’UTR at two adjacent sites (Jangra et al 2010, Jopling 2008,
Norman and Sarnow 2010).
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Figure 3.3. Effect of different statins and mevalonate on the HCV replication, cellular
morphology and cell survival within three days of the drug treatment. (A) Relative
abundance of the HCV RNA in FLV-treated cells that were supplemented with 5, 10 and
15 uM of mevalonic acid (antagonist of FLV). The untreated culture was used as
positive control. (B) Western blot for detection of NS5B expression levels in GS5 cells
treated with fluvastatin (FLV, lanes 2, 3), pravastatin (Prav, lanes 4, 5) and rusovastatin
(Ruso, lanes 6,7). Lane 1, untreated control. DMSO, vehicle control. (C) Brightfield
photograph of GS5 cells treated and untreated with various drugs as indicated,
highlighting morphological sensitivity of the cells by the FLV treatment (b) and its partial
reversal by mevalonate (d). a, b; controls. (D) MTT assay for cell proliferation at 72 hrs
of the FLV and vehicle treatments. ASPC1, pancreatic cell line; FCA4, hepatoma cell
line derived from Huh7 and expresses a subgenomic replicon without GFP, otherwise
similar to the GS5 cells.
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Figure 3.4. Effect of FLV on microtubule filaments (MTFs) in GS5 (A), normal human
hepatocytes [(C), upper panel] and Huh7.5 cells [(C), lower panels] shown by confocal
microscopy. (B) Higher magnification for vehicle (DMSO alone) treated GS5 cells [(A),
upper panel] showing localization of the HCV replication complexes (green), MTFs (red)
and their colocalization (yellow).
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The miR-122 has also been implicated in cholesterol biosynthesis. For these
reasons, we checked if primary miR-122 RNA is affected by the FLV in GS5 cells. As
shown in figure 3.6A, DCAMKL-1 RNA (black bar) but not the pri-miR-122 (Fig. 3.6B)
level was reduced to significant extent by the FLV treatment. In the control DMSO
sample neither DCAMKL-1 nor pri-miR-122 RNA levels were affected. These results
clearly suggest that FLV regulates expression of DCAMKL-1 at its RNA level, and the
existing DCAMKL-1 localization to the MTFs is severely affected.

The net result of

FLV effect is reflected by inhibition of the HCV expression in these cells.

3.5. Cirrhotic liver nodules of chronic HCV patients show overexpression of
DCAMKL1 and CK19

As a continuing effort to unravel the mechanism of HCC development, we
examined liver biopsy samples from chronic HCV patients and liver tissue arrays
representing various stages of liver diseases.

An example of immunohistochemical

staining result is shown in Fig. 3.7. Strikingly, in agreement with the results obtained for
our cell culture and xenograft experiments, the biopsies exhibited overexpression of
DCAMKL1 and CK19 in the cirrhotic liver nodules which are considered to be risk
factor for hepatocarcinogenesis (Fig. 3.7 lower panel). DCAMKL-1 expression was also
shown to be increased in cirrhotic liver tissue as shown by our tissue microarray studies
(Appendix 3).
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Figure 3.5. Immunoflorescence microscopy localization of DCAMKL-1 (red) in relation
to MTFs (magenta) and replication complexes (green). The GS5 cells were treated with
DMSO or FLV as indicated.
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The findings described in this chapter are coherent with those in Chapter 2. Our
data further support possible use of the FDA-approved drug, fluvastatin as an adjuvant to
the available HCV therapeutics in order to reduce the risk of HCC development. In
addition, it is likely that FLV along with DCAMKL-1 antagonist would effectively block
both chronic HCV infection as well as HCV-induced HCC.

4. Discussion

We demonstrated inhibitory effects of fluvastatin (FLV) on the abundance of
HCV RNA and NS5B polymerase in cell culture. This pleiotropic effect was only
partially restored by large excess (3 times molar excess) of the FLV antagonist
(mevalonate), which indicates involvement of additional mechanism for the FLV-led
inhibition of HCV besides partial contribution of the cholesterol biosynthesis pathway.
This notion is also supported by the fact that only fluvastatin but not pravastatin reduces
the HCV NS5B level and exerts induced-bundling of microtubule filaments. One of the
obvious consequences of the MTF bundling was highly pronounced morphological
changes in GS5 cells than that of the parental Huh7.5 cells. Our cell viability assays
suggested that these cells were still alive during 3-day of FLV treatment. Interestingly,
normal human hepatocytes derived from a healthy donor were completely tolerant to
FLV treatment and did not exhibit the MTF bundling. The selective MTF bundling in
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Figure 3.6. Effect of fluvastatin on the abundance of DCAMKL-1 and pri-miR-122
RNAs. The GS5 cells were treated with varying amounts of FLV (black bar) or DMSO
alone (gray bar) and total RNAs isolated from these cells were subjected to real-time RTPCR
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cancer cells induced by FLV is likely affecting microtubule dynamics and its associated
proteins. In previous chapter, it was demonstrated that HCV induces overexpression of
the microtubule-associated putative stem cell marker, DCAMKL-1.

Houchen and

colleagues from this department (May et al 2008, Sureban et al 2009) have previously
shown that both pancreatic and colon cancer cells exhibit high expression of DCAMKL-1
and develop tumors in a mouse xenograft model. However, when DCAMKL-1
expression was inhibited in the tumors, the tumor size shrinks dramatically. These
observations prompted us to investigate the status of DCAMKL-1 in FLV-treated cells.
We demonstrated that DCAMKL-1 RNA abundance was reduced in these cells and the
existing DCAMKL-1 protein was aggregated and dislodged from the microtubule
filaments. As a result, the HCV replicon expression was significantly reduced because
intact MTFs and DCAMKL-1 (as presented in chapter 2) are required for the HCV
replication (Lai et al 2008, Roohvand et al 2009) (Wolk et al 2008).

HCV is regarded as a lipoviroparticles because lipids play pivotal roles in the
organization of HCV particles as well as infectious processes of the virus. Cholesterol
esters account for nearly half of the total lipid content of cell culture generated HCV
infectious particles. Both HCV NS5A and core proteins are known to associate with lipid
droplets (LD) that are cellular lipid storage organelles involved in lipid homeostasis.
Chronic hepatitis C virus (HCV) infection affects host lipid metabolism and induces LD
accumulation in the liver. In addition, the ‘niche’ of active replication of the HCV RNA
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Figure 3.7. CK19 and DCAMKL-1 overexpression in an HCV-positive patient liver
detected by immunohistochemistry. Sample 2 represents neoproliferative cells in the
cirrhotic liver biopsy taken after 2 years of the first biopsy (Sample 1) from the same
patient. Brown stain, DCAMKL-1 and CK19; Blue stain, nucleus.
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complexes consists of the viral NS proteins including NS5A and lipid rafts that are
enriched in caveolin-2, sphingomyelin and cholesterol. It has been suggested that
geranylgeranylation of a cellular protein, F-box/leucine-rich repeat protein 2 (FBL-2) in
an HMG-CoA reductase (HMGCR)-dependent manner is required for its interaction with
the HCV NS5A protein and its role in HCV RNA replication. In such situation,
supplementation of mevalonate would have completely rescued the HCV replication as it
functions as a substrate downstream of HMGCR activities. These observations also
argue FLV-mediated control of HCV abundance in favor of its selective effects on
MTFs-dependence DCAMKL-1. Because the HCV replicon expressed in GS5 cells lacks
all of the structural proteins (C, E1 and E2) and assembly of the particle, the observed
FLV effect is likely to be directed at the translation and replication steps.

Chronic HCV infection over several months to a few years results in cirrhosis
including disruption of normal liver architecture and development of regenerative
nodules.

We examined multiple nodules from HCV-positive cirrhotic liver.

The

immunohistochemistry results clearly showed overexpression of both DCAMKL-1 as
well as CK19 in these nodules. In many cases, such nodules are considered to be
precursors for the development of HCC (Caillot et al 2009). Therefore, FLV inclusion in
the treatment of chronic HCV infection will have multiple advantages. First, it will
reduce cholesterol biosynthesis and disrupt the excessive accumulation of lipid droplets
and lipid-rafts, which are required in the replication, assembly and intracellular transport
of HCV.

Second, generally well-tolerated fluvastatin may reduce the risk of HCC

development due to its effects on DCAMKL-1 and MTFs. It has been shown by other
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investigators that the plieotropic effects of statins act as adjuvant to other HCV targeting
drugs, and may sensitize the cells against anti-neoplastic drugs (Demierre et al 2005).

In conclusion, the studies presented in this chapter clearly strengthen this notion
and recommends inclusion of fluvastatin with new HCV-specific drugs (e.g. boceprevir)
for

the

treatment

of

chronic

96

infection

and

HCC.

Chapter Four: Mechanism of c-Src proto-oncogene expression in
HCV expressing cells

1.

Introduction
The studies on tumor xenotransplantation (Chapter 2, Fig. 2.3E) suggest that c-

Src, a prominent member of the non-receptor tyrosine kinase family, was highly
expressed and activated in the area rich in DCAMKL-1. This led us to believe that c-Src
expression may be important factor for the HCV-induced carcinogenesis. The level of
cellular Src (c-Src) protein, is known to increase in a variety of tumors (Fizazi 2007,
Horn et al 2003). However, it is not known whether the enhanced expression is regulated
by transcriptional and/or post-transcriptional mechanisms. The c-Src protein promotes
cell differentiation, tumor growth, metastasis and angiogenesis (Bjorge et al 2000, Finn
2008).

It activates STAT3 which transcriptionally regulates expression of Bcl-XL, c-

Myc and cyclin D1 leading to activation of anti-apoptotic and cell-cycle progression
pathways (Diaz et al 2006, Garcia et al 2001).

It has been shown that activated c-Src-

focal adhesion kinase (FAK) complex promotes cell mobility, cell-cycle progression and
cell survival. The c-Src activities are also important for promoting VEGF-associated
tumor angiogenesis and protease-associated metastasis (Mitra and Schlaepfer 2006).
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Post-translational modifications such as phosphorylation and myristoylation are
key regulators of the c-Src activities. While non-myristoylated c-Src readily moves to the
nucleus in G0 and at the G1/S phase, myristoylation at the N-terminus is required for its
membrane attachment and transforming activities (David-Pfeuty et al 1993, Oneyama et
al 2008).

The intramolecular interaction between its SH2 domain and phosphorylated
Tyr530 (numbered according to NM_198291) residue at the C-terminus induces closed or
inactive conformation in the c-Src molecule. Under basal conditions in vivo, 90-95% of
Src is found in this state (Zheng et al 2000). The dephosphorylation of Tyr530 by protein
tyrosine phosphatase (PTP) and autophosphorylation of Tyr419 by its kinase domain
causes induction of an enzymatically active, open conformation(Bjorge et al 2000, Fizazi
2007).

The Src gene is composed of 14 exons (Bonham and Fujita 1993, Bonham et al
2000). Transcription of this gene in hepatoma cells from two different promoters and
alternative splicing results in mature transcripts that differ only in the extreme 5’ ends but
encode the same 60 kDa c-Src protein (Fig. 4.1A). The c-Src Type-1A mRNA contains a
350 nt long 5’ noncoding or untranslated region (5’NCR or 5’UTR) with multiple AUGs
located at nt positions 147, 179, and 351 (Fig 4.1B). However, only AUG351 is used to
initiate translation of the c-Src open reading frame (ORF). The Type-1a c-Src transcript
contains a 451 nt long 5’NCR and differ with Type-1A only in the first exon (1A or 1a)
(Bonham et al 2000). The second and third exons (1B and 1C) are shared in both
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transcripts. Hepatoma cells have been shown to express both transcripts (Bonham et al
2000). The regulatory role(s) of these noncoding/untranslated elements during translation
of c-Src mRNAs and their role(s) in c-Src overexpression are not known.

Most eukaryotic mRNAs are translated by cap-dependent mechanism where
eIF4F complex binds to the 5’ cap structure through its eIF4E subunit (Sonenberg and
Hinnebusch 2007). This binding event results in activation of mRNA and assembly of
48S pre-initiation complex. The 48S complex scans mRNA in 5’ to 3’ direction until an
appropriate AUG initiation codon is encountered, which is followed by joining of the 60S
subunit (Sonenberg and Hinnebusch 2007). Many cellular conditions such as apoptosis,
stress, mitosis, heat-shock, hypoxia, infections and nutrient deficiency alter the function
of normal translation initiation machinery. This is largely affected by post-translational
modifications (e.g. phosphorylation) and/or cleavage of canonical initiation factors (e.g.
eIF4B, eIF3, eIF2a and eIF4G family members) (Baird et al 2006, Sonenberg and
Hinnebusch 2007, Wek et al 2006). A considerable number of cellular and viral mRNAs
have been shown to be translated by cap-independent mechanism due to the presence of
an IRES element in the mRNAs (Hellen and Sarnow 2001, Johannes and Berger 1993).
Nearly 125 IRES elements have been described in a variety of species ranging from
viruses to humans (Baird et al, 2006). The IRES elements have been detected in a
number of eukaryotic mRNAs that encode proteins involved in signal transduction
pathways, gene expression and development, differentiation, apoptosis, cell-cycle or
stress response (Holcik and Sonenberg 2005, Lewis et al 2008, Sonenberg and
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Hinnebusch 2007). For example, cellular stress causes dephosphorylation of eIF4E and
hypophosphorylation of 4E-BPs, both of which are unfavorable for the assembly of
translation pre-initiation complex by the cap-dependent mechanism (Gingras et al 1999,
Sonenberg and Hinnebusch 2007).

However, under these conditions, Bcl-2, XIAP,

eIF4G, VEGF, ODC, PDGF, PITSLRE, c-Myc family members, and a whole host of
proteins maintain their presence due to their IRES-controlled translation(Chappell et al
2000, Johannes and Sarnow 1998, Nanbru et al 1997, Semler and Waterman 2008,
Spriggs et al 2008).

All of the viral and cellular IRESs initiate translation of a downstream open
reading frame (ORF) by cap-independent mechanism in spite of their rich structural
diversities (Filbin and Kieft 2009). The distinct structural features allow the IRESs to
attract different set of canonical and non-canonical translation factors for their efficient
activities and/or regulation. For examples, some of the viral and cellular IRESs require
initiation factors such as eIF4G and PABP while others show enhanced activities when
these factors are cleaved or their function is inactivated (Holcik and Sonenberg 2005). A
few of the IRESs seek support from ITAFs (IRES-specific trans-acting factors) such as
hnRNP family members, PTB, La antigen and PCPB for their efficient function (Ali and
Siddiqui 1997, Semler and Waterman 2008, Spriggs et al 2008, Wang et al 1995). The
IRESs also exhibit variations in the mode of assembly of pre-initiation complex.
Poliovirus-like IRESs recruit the 48S pre-initiation complex upstream of the initiation
site and require scanning of the complex for the initiator AUG codon, whereas an
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extensively studied encaphalomyocarditis virus (EMCV) IRES recruits the pre-initiation
complex at the initiation site that includes AUG (Baird et al 2006, Filbin and Kieft 2009).
The IRESs of hepatitis C virus (HCV, a hepacivirus), classical swine fever virus (CSFV,
a pestivirus), cricket paralysis virus (CrPV, a dicistrovirus) and simian picornavirus type
9 (SPV9) constitute a distinct class because of their ability to directly bind and make
multiple contacts with the 40S ribosomal subunit (Filbin and Kieft 2009, Jan and Sarnow
2002, Lancaster et al 2006, Pestova et al 1998). The assembly of productive initiation
complexes on these IRESs is energy-efficient and can ignore the need of several critical
translation initiation factors (eIFs 4F/4A/4B/1/1A) that are controlled by a variety of
external and internal cellular regulators (Robert et al 2006, Spriggs et al 2008). This
‘40S-binding signature’ has not been reported for the known cellular IRESs.

2. Material and Methods

2.1. Plasmid Constructs

RNA was isolated from hepatoma-derived Huh7 cell line using Qiagen RNeasy
kit. Nucleotides 1-383 of the Type-1A c-Src mRNA were amplified from the total RNA
using high fidelity RT-PCR Kit (Promega) and a pair of primers (Sense:
5’CATAGCAAGCTTGCCGGAGCGGCCAGGCCGCCGTCTGC3’;

Antisense:

5’GCGCCGCTGTCATGAGGCATCCTTGGGCTTGCTCTTGTTGCTACC3’,
restriction enzymes sites are underlined). The amplified DNA contains wild type fulllength 5’NCR and 33 nt coding region that encodes first 11 aa of the c-Src protein. The
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PCR products were digested with HindIII and BspHI for ligation into a vector backbone.
The backbone was created by digestion of a previously described plasmid pT7C1-DC29332 (Wang et al 1993) with HindIII and NcoI and the PCR products were ligated at this
site after restriction digestion. The resulting plasmid p5'Src-FLuc contains T7 promoter
at the 5’ end of the c-Src sequence which is followed by ORF of firefly luciferase (FLuc)
and ends with oligoA tail. The in vitro transcription of the HpaI digested plasmid by T7
RNA polymerase produces an RNA containing the entire 5’NCR followed by coding
sequences representing N-terminus 11 aa (MGSNKSKPKDA) of c-Src fused with the
FLuc ORF ending with poly(A) tail. The plasmid p5'Src∆C-FLuc was similarly
constructed as described for p5'Src-FLuc except that it lacks 33 nt of the c-Src coding
sequence. To construct this plasmid, the c-Src PCR-amplified DNA described above was
digested with HindIII and NcoI and cloned at the same site in the vector backbone. In
both cases the Kozak sequence context was maintained at the translation site. The
sequence of each construct was verified by restriction enzyme digestion and Big Dye
DNA sequencing method (Applied Biosystems).

The mutant plasmids p5'Src∆1-FLuc, p5'Src∆2-FLuc, p5'Src∆3-FLuc are derived
from the p5'Src-FLuc except that these plasmids have deletions of 19 (nt 216-350), 253
(nt 95-348) and 171 (nt 47-216) bases in the c-Src motif respectively. The plasmids were
constructed by appropriate restriction digestion and religation of the open ends. A dual
luciferase plasmid construct (p5'Src-RFLuc) was engineered which contains renilla
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luciferase (RLuc) gene and stop codon upstream of the c-Src 5’NCR in the original
plasmid p5'Src-FLuc.

The plasmid 5’PV-FLuc contains wild type, full-length poliovirus (PV, Mahoney
strain) 5’NCR (nt 1-742) cloned in frame with FLuc ORF followed by poly(A) tail. The
mutant plasmid 5’PV(D286-605)-FLuc was constructed by restriction enzyme digestion
of the 5’PV-FLuc plasmid with BlpI and BsaBI followed by filling with T4 DNA
polymerase and religation with Quick T4 DNA ligase (New England BioLabs). The
resulting plasmid contains a deletion of 319 bp (nt 286-605) in the PV 5’NCR.

2.2. In vitro transcription

The plasmids p5'Src-FLuc, p5'Src∆1-FLuc, p5'Src∆2-FLuc, p5'Src∆3-FLuc and
p5'Src∆C-FLuc were linearized with HpaI and transcribed with T7 RNA polymerase to
produce luciferase reporter RNAs. The uncapped RNAs were prepared with Promega’s
RiboMax Large Scale RNA production kit. The capped RNAs were synthesized in the
presence of the ARCA cap analogue using mMassage mMachine Ultra kit (Ambion) in
accordance with the manufacturer's instructions. The transcribed RNAs were passed
through G25 column and purified by extraction with phenol:chloroform:isoamyl alcohol
(PCI) followed by water-saturated cold ether. Following precipitation and washing with
70% ethanol, the final preparations were dissolved in RNase-free water and checked for
integrity of RNAs by formaldehyde-agarose gel electrophoresis. Concentrations of RNA
were determined spectrophotometrically. For preparation of the c-Src NCR probe, 5’Src103

FLuc was linearized with XbaI and transcribed with T7 RNA polymerase in the presence
of [a-32P]CTP.

The 5’PV(D286-605)-FLuc was similarly digested with XbaI and

transcribed for preparation of an inactive IRES control probe. The probes were purified
using Qiagen RNeasy purification method. The plasmid pRL-HCV1b encodes upstream
Renilla luciferase followed by the HCV IRES (nt 1-357 of the HCV genotype 1b) linked
to the second reporter FLuc (Collier et al 1998). The plasmid was linearized with HindIII
and transcribed in the presence of cap analogue using T7 RNA polymerase.

2.3. Cell culture and preparation of cell lysates

Huh7 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 1x Pen/Strep and 10% fetal bovine serum (Invitrogen), and
maintained at 37°C and 5% CO2. HeLa S3 cultures were carried out in spinner flask
containing Joklik modified minimum essential medium Eagle (Sigma) supplemented with
5% bovine calf serum, 2% fetal clone II (Hyclone), 1x Penicillin/Streptomycin, and
incubated at 37°C and 5% CO2.

HeLa translation lysates (S10) and lysates containing initiation factors (IFs) were
prepared according to the protocol described by Barton and colleagues (Barton et al
1996).

The rabbit reticulocyte lysate nuclease-treated (RRL) was purchased from

Promega. The total lysates from cultured Huh7 cells were prepared using M-PER Kit
(Pierce) as instructed.
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2.4. In vitro translation of RNAs

The in vitro transcribed wild type 5’Src-FLuc and its mutant derivatives were
translated in HeLa cell-free system. The standard HeLa cell-free translation mixtures
contain 20 ul S10, 10 ul IFs, 5 ul 10X buffer (155 mM HEPES-KOH, pH 7.4, 600 mM
potassium acetate, 10 mM ATP and 2.5 mM GTP, 300 mM phosphocreatine, 4 mg/ml
creatine phosphokinase), 20 units RNasin, 5 to 10 ug RNA template in a 40 ul final
volume. One microliter [35S]Methionine was added for radio-labeling of the newly
synthesized proteins. The translation mixtures were incubated for 1 to 2 hr at 30°C, and
the FLuc activity was assayed using 2 ul aliquots. For detection of protein bands, the
samples were subjected to SDS-PAGE followed by autoradiography. For detection of the
5’Src-RFLuc RNA expression, a dual luciferase assay protocol (Promega) was employed,
and renilla and firefly luciferase activities were simultaneously assayed.

Varying

amounts of m7 GDP or m7GTP were added in the standard HeLa translation mixtures for
inhibition of cap-dependent translation. Unmethylated GDP or GTP served as negative
control. Translation of the RNA in RRL was carried out as described in the supplier’s
protocol (Promega).

2.5. RNA stability assay
Equal amounts of 32P-labeled wild type or mutant reporter RNAs were incubated
in standard HeLa translation reactions and total RNAs were extracted from each sample
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using RNeasy Kit (Qiagen). The recovered RNAs were subjected to formaldehydeagarose gel electrophoresis followed by autoradiography of the dried gel. The bands of
18S or 28S rRNA in each lane were measured by ethidium bromide staining before
drying the gels. During transfection experiments,
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P-labeled reporter RNAs (1-2x106

dpm) were transfected into Huh7 cells using standard transfection method and total
RNAs were isolated.

The radioactive full-length RNAs were detected by

autoradiography.

2.6. Transfection of RNA into cells

Huh7 cells were transfected with in vitro transcribed RNAs using Lipofectamine
2000 reagent (Invitrogen) according to the manufacturer’s protocol. After 3, 5, 8, 24 and
48 hours post-transfection, the cells were harvested and resuspended with lysis buffer
(100 mM potassium phosphate pH 6.8, 1 mM DTT, 0.5% Igepal). The samples were
then subjected to two freeze-thaw cycles and supernatants were assayed for Luc
activities.

For fluorescence microscopy, the cells were grown on coverslips (Fisher

Scientific) followed by RNA transfection. The cells were fixed with 4% formaldehyde
48 hours post-transfection, permeabilized and stained with anti-firefly luciferase
monoclonal antibody (Bionovus). A FITC-labeled secondary conjugate was used to
visualize the FLuc distribution in the transfected cells.
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2.7. Isolation of 40S ribosomal subunit

HeLa S10 lysate was prepared from HeLa S3 cells grown in a spinner flask as
described by Barton and colleagues (Barton et al 1996). The ribosomes were pelleted
from S10 lysate by centrifugation in Ti70.1 rotor (Beckman, 45,000 rpm) for 3h at 4 °C
and the pellet was resuspended in buffer A (20 mM Tris-HCl, pH 7.5, 2 mM DTT, 50
mM KCl, and 4 mM MgCl2 ) at a concentration of 150 U/ml measured at A260 as
described by Pisarev et al. (Pisarev et al 2007). Puromycin (1 mM) and KCl (0.5 M)
were added, stirred at ice-bath for 10 min followed by incubation for 10 min at 37°C.
The mixture was then loaded onto a 10%-30% sucrose density gradient and centrifuged
for 16 h at 4 °C in a Beckman’s SW28 rotor (22,000 rpm). The peak fractions containing
40S ribosomes (as determined by the presence of only 18S rRNA) were pooled and
concentrated in Ultracell-100 K (Millipore). The final preparation was dialyzed in buffer
C (20 mM Tris-HCl pH 7.5, 2 mM DTT, 100 mM KCl, 2 mM MgCl2, 0.25 M sucrose),
aliquoted and stored at -80 °C (Pisareva et al 2008).

2.8. Sucrose density gradient analysis

Capped or uncapped
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P-labeled mRNAs were incubated in standard HeLa

translation lysates that were treated with 1mM GMP-PNP for 5 min on ice-bath. The
mixtures were then incubated for 15 min at 30°C, layered onto a 10%-30% sucrose
gradient in buffer K (20 mM Tris-HCl pH 8.0, 100 mM potassium acetate, 5 mM
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magnesium acetate, and 2 mM DTT), and centrifuged for 3 hours at 45,000 rpm and 4
°C in a SW-51 rotor. Fractions (250 ul) were collected from the bottom of gradient and
analyzed by scintillation counter. Total RNAs from peak fractions were isolated using
Qiagen RNeasy Mini column for analysis of the RNA contents in the fractions.

For 40S-IRES binary interaction assay, the
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P-labeled c-Src IRES or

a

nonspecific RNA probe derived from 5’PV(D286-605) as scrambled IRES was mixed
with purified HeLa 40S subunit in buffer K containing 20 U RNasin in a final volume of
40 ul and incubated for 15 minutes at 30°C. The reaction mixtures were analyzed by
sucrose density gradient method as described above. A sample of RNA probe without
40S was used to specify position of the free probes during centrifugation.

3. Results

3.1. Cellular stress induces c-Src overexpression as well as its activation

Our mouse xenograft experiments (Chapter 2, Fig. 2.3E) clearly demonstrated
that sporadic DCAMKL-1 expressing cells were embedded in the GS5 tumor areas
where c-Src oncoprotein was overexpressed. It has been established by other studies that
stress is one of the culprits for inducing tumorogenesis (Alvarez et al 2006, Chang et al
2007, Diaz et al 2006, Horn et al 2003).Since HCV induces oxidative stress and NF-k
(Waris et al 2005), we investigated molecular mechanism of c-Src expression under
cellular stress that impairs cap-dependent translation.
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Thapsigargin (TG) causes eIF-2 phosphorylation resulting in global translation
inhibition and ER stress response due to inhibition of Ca2+-ATPase activities (Chao et al
1997, Wong et al 1993). A modest increase in the total c-Src protein level was observed
in DMSO-TG-treated cell lysates as compared to the untreated (control) or DMSO alonetreated lysates (Fig. 4.1.A). The c-Src mRNA level remained unchanged in these cells
(Fig. 4.1B). Serum-deprivation of cells also causes suppression of cap-dependent
translation due to competitive inhibition of eIF4E binding to the 5’ cap structure by
poly(A)-specific ribonuclease (PARN) (Seal et al 2005), and phosphorylation of eIF2a
(Wek et al 2006). When Huh7 cells were subjected to serum starvation, the total c-Src
protein level was moderately enhanced within 72 hours (Fig. 4.1.C, minus) as compared
to the control (plus) although the c-Src mRNA level was not affected (Fig. 4.1.D).

3.2. Characteristics of the computer-generated c-Src RNA structures

The 5’NCRs in the c-Src transcripts have been shown to be relatively longer than those in
most cellular mRNAs (Bonham and Fujita 1993). Sequence analysis revealed multiple
pyrimidine-rich motifs and two cryptic AUGs with short ORFs at positions 147 and 179
in the 350-nt long Type-1A 5’NCR (Fig. 4.2). Only the AUG located at position 351 is
known to serve as the initiator codon in this mRNA. Our nucleotide blast search using
BLASTN 2.2.20+ program (Schwartz et al 2000)revealed that the exon 1C and 11 amino
acid N-terminus coding sequences are highly conserved in humans, chimpanzees and
rhesus monkeys (94%-100% identity) whereas mouse sequences in this region are 7680% identical to the reference human c-Src mRNA sequences (NM_005417.3 and
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NM_198291). Using M-Fold program (Zuker 2003), we examined a number of predicted
secondary structures representing three segments (nt 1-353, 1-383, 1-410) of the Type-1A
c-Src mRNA. A representative structure (dG = -135) for nt 1-383, which was found to be
similar to the structure obtained for nt 1-410 segment, is shown in (Fig. 4.3) This Yshaped secondary structure appears to contain three domains designated as domain I, II
and III. We further observed that a large portion of the domains I and II were conserved
in the structures predicted for all three c-Src segments. In addition, a high degree of
conservation in the apical loops contributed by AACAAGA (nt 360-366), GUGCCA (SL
II, nt 289-294) and UAUUUC (SL III, nt 255-260) motifs was also noticed in the
predicted structures. The structures in domain III, however, showed less conservation
among various structures generated for the three c-Src segments. A 14 nt pyrimidine
(Py)-rich motif (nt 330-344) is located 6 nt upstream of the initiator AUG, which
conforms Py-tracts found in many viral IRESs. These characteristics and the Y-shaped
architectural features are considered as important elements of many viral and cellular
IRESs (Le and Maizel 1997). The predicted structure for the c-Src nt 1-353 that
represents the entire 5’NCR and AUG codon lacked a significant portion of domain II
structure.

3.3. A c-Src mRNA motif supports cap-independent translation of reporter
RNAs

Firefly luciferase (FLuc)-based reporter mRNAs were engineered to test if the cSrc 5’NCR supports cap-independent translation (Fig. 4A). Because a 33-nt sequence
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Figure 4.1. A, The cytoplasmic lysates from experiments described in section B (above)
were subjected to Western blot for the total c-Src protein with monoclonal anti-Src
antibody (clone 327, Santa Cruz, upper panel) or anti-actin antibodies (lower panel). B,
Northern blot analysis of total RNA extracted from Huh 7 cells described in section B,
probed with 32P-labeled oligonucleotide corresponding to nt 320-350 of the c-Src 5’NCR
(upper panel). Lower panel shows 18S rRNA in the same samples. C, Total c-Src level
in Huh7 cell lysates cultured for 72 hrs in serum-deprived (indicated as minus) or 10%
serum containing (plus) media. Western blot was carried out with anti-Src antibody as
described above. D, Northern blot for probing c-Src mRNA (as described above) in total
RNA extracted from Huh 7 cells cultured in serum-starved (minus) and serum
supplemented (plus) regular media. The 18 S rRNAs in each lane is shown in the lower
panel.
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Figure 4.2. A, Organization of the c-Src gene. Transcription from two promoters
(indicated as P) and alternative splicing result in Type-1a (NM_005417) and Type-1A
(NM_198291) mRNAs in liver cells. Both transcripts differ only in the 5’ distal region of
the 5’NCR. The sequence of the exons 1B and 1C and open reading frame (ORF) are
shared in both transcripts (35). AUGi, initiator AUG codon. B, Schematic of the Type1A 5’NCR. Two cryptic AUGs at nt 147 and 179, the initiator AUG at nt 351, and a
pyrimidine-tract (nt 330-344) located 6 nt upstream of the initiator AUG are shown. The
gray lines with arrows on both sides show sequence locations in different putative
domains whereas similar arrows with black solid lines indicate position of the conserved
stem-loop structures as shown in Fig. 4.2
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motif downstream of the initiator AUG in the c-Src mRNA forms conserved stem-loop
structure at the translation initiation site (Fig. 4.3), we included the region with the
5’NCR for engineering a parent reporter 5’Src-FLuc RNA. The RNA contains c-Src nt
1-383 (full-length 5’NCR plus 33 nt of the coding region) that is fused in-frame with
luciferase ORF and ends with poly(A) tail (Fig. 4.4A). In vitro transcribed capped and
uncapped RNAs were translated in rabbit reticulocyte cell-free lysate (Michel et al 2000,
Soto Rifo et al 2007) in the presence of [35S]Methionine and the synthesized products
were visualized by autoradiography. As expected, the capped 5’Src-FLuc RNA was
translated to produce active luciferase protein (Fig. 4.4B, lane 3). than its capped
counterpart (lane 3). During the assay, we used a reporter RNA [5’PV(D286Interestingly, the uncapped 5’Src-FLuc RNA was also translated but with higher
efficiency (lane 2) (from nt 286 through 605). Thus, the noncoding region (420 nt) in the
mutant PV construct represents nt 1-285 followed by nt 606-746 of the PV 5’NCR. This
PV region, although, is known to form stable stem-loop structures, provides stability to
the RNA and binds a number of cellular factors (Murray et al 2001), failed to support
translation of FLuc in RRL (lane 4). However, synthesis of FLuc was successfully
achieved when the same RNA had 5’m7G cap structure (lane 5). These results clearly
demonstrate that the c-Src nt 1-383 allows cap- independent translation of downstream
ORF and its activity is enhanced when cap function is absent. The translatability of the
mRNA constructs was further tested in HeLa cell-free translation lysates which has been
widely used for investigating IRES-mediated translation initiation (Barton et al 1996).
An uncapped reporter FLuc RNA that contains wild-type, full-length PV 5’NCR (5’PV113

Figure 4.3. Computer-assisted folding of the Type-1A c-Src mRNA sequence. The
Zucker’s M-Fold program (version 3.2, 41) was used for prediction of the secondary
structures representing various segments of the c-Src mRNA. Only a representative
structure of the c-Src nt 1-383 that includes the entire 5’NCR followed by 33 nt coding
sequence, is shown here. The initiator AUG at position 351 (arrow), and putative stemloop (SL) structures, domains and nt positions are indicated.
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FLuc, Fig. 4.4C, lane 4) and 5’Src-FLuc (lane 2) were efficiently translated while the
mutant 5’PV(D286-605)-FLuc again failed to support synthesis of luciferase (lane 3).
Next, we examined the c-Src 5’NCR- promoted translation in the context of a dicistronic
mRNA (5’Src-RFLuc). The RNA is similar to the monocistronic 5’Src-FLuc RNA except
that it contains renilla luciferase (RLuc) ORF and stop codon upstream of the c-Src
sequence (Fig. 4.5A).

The in vitro transcribed capped RNA was transfected into

hepatoma Huh7 cells for 3 hr and the lysates were subjected to dual luciferase assay. As
shown in Fig. 4.5B, both ORFs were translated in these cells. The capped dicistronic RLHCV1b and RL-Vector RNAs were used as positive and negative controls respectively
during the transfection. The RL-HCV-1b is similar to the 5’Src-RFLuc (Fig. 4.5A)
except that the translation of downstream FLuc ORF is controlled by the HCV IRES
instead of the c-Src IRES. In RL-Vector, the c-Src IRES between upstream RLuc and
downstream FLuc ORF is deleted. Both of the RNAs produced results as expected
(Appendix 5). In a parallel experiment, total RNAs isolated from the dicistronic 5’SrcRFLuc RNA-transfected cells were subjected to Northern blot analysis using a
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labeled oligonucleotide probe that detects 3’ end of FLuc ORF. The result showed that
the dicistronic RNA was intact in the transfected cells (Fig. 4.5C, lane 3). The migration
of isolated RNA was similar to that of in vitro transcribed dicistronic RNA (lane 2), and
was not cleaved into monocistronic form (lane 1). The 5’Src-FLuc RNA encodes a
chimeric firefly luciferase with aa 1 to 11 (MGSNKSKPKDA) of the c-Src protein at its
N-terminus (Appendix 4A). This c-Src motif has been shown to play important role in
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Figure 4.4. c-Src 5’NCR-mediated translation in cell-free lysates. A, Organization of in
vitro transcribed uncapped reporter RNAs. The 33 nt coding sequence (dotted box, C),
and Kozak sequence are shown at translation initiation site. The solid line represents
5’NCR. An, poly(A) tail. B, Five ug of uncapped (lanes 2, 4) and capped (lanes 3, 5) of
5’Src-FLuc (lanes 2, 3) or 5’PV(D286-605)-FLuc (lanes 4, 5) RNAs were translated in
RRL for 1.5 hr in the presence of [35S]Methionine. The FLuc protein bands were
visualized by autoradiography after SDS-PAGE. Two ul of the translation lysates were
assayed for enzymatic activity (shown as RLU) of FLuc using D-luciferine substrate.
Lane 1, translation without exogenous RNA (control). C, Translation of uncapped 5’SrcFLuc (lane 2), 5’PV(D286-605)-FLuc (lane 3) and 5’PV-FLuc (lane 4) RNAs in HeLa
cell-free lysate as described above. The FLuc activity and the protein bands are shown.
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membrane localization and translocation of the protein into the nucleus (David-Pfeuty et
al 1993, Resh 1999). Transfection of an uncapped 5’Src-FLuc RNA into Huh7 cells
resulted in the synthesis of luciferase protein that was primarily localized in the nucleus
and perinuclear membranes (Appendix 4). This observation was in sharp contrast to the
diffused cytoplasmic localization of luciferase that was encoded by 5’HCV-FLuc RNA in
which translation of FLuc occurs under the control of HCV IRES. The resulting FLuc
lacks c-Src aa 1 to 11 motif. These results suggest that the luciferase synthesized from
5’Src-FLuc RNA contains the c-Src protein motif, which is possible when translation is
initiated at the authentic AUG351 (also see Fig. 4.6 for translation of 5’SrcD1-FLuc).

3.4. Identification of an IRES element in the c-Src mRNA

We introduced several deletion mutations in c-Src motif of the 5’Src-FLuc RNA
to determine its putative IRES function. The mutant 5’SrcDC-FLuc is similar to the wild
type 5’Src-FLuc RNA except that it lacks the c-Src coding sequence (nt 354-383, Fig.
4.6A). The mutant 5’Src-D1-FLuc contains a 19 nt deletion (nt 344-362). This deletion
resulted into the loss of Kozak sequence and a major portion of SLI structure at the
translation initiation site (Figs. 4.3 and 4.6A). As shown in Fig. 4.6B, both of the
deletions caused dramatic reduction in the synthesis of FLuc (lanes 4, 7) as compared to
the wild type RNA (lane 3). Similarly, the 5’SrcD2-FLuc mutant RNA that contains a
large deletion (nt 95-348) upstream of initiator AUG also failed to support efficient
synthesis of FLuc (lane 5). Unlike these mutants, a 5’SrcD3-FLuc RNA that maintains nt
1-47 and 216-383 of the c-Src mRNA showed cap-independent translation of FLuc
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Figure 4.5. c-Src 5’NCR-mediated translation in Huh7 cells. A, Schematic of an in
vitro transcribed dicistronic reporter mRNA (5’Src-RFLuc). B, The Huh7 cultured cells
(80% confluency, 50 mm dish) were transfected with 10 ug capped 5’Src-RFluc for 3 hr,
and renilla and firefly luciferase activities were assayed in the cytoplasmic fractions.
Each transfection was carried out in triplicate, and the experiment was repeated three
times to confirm the results. The cytoplasmic fractions of untransfected cells were used
as negative control. C, Northern blot analysis of total RNA isolated from 5’Src-RFLuctransfected (lane 3) and untransfected (lane 4) Huh7 cells. Lanes 1 and 2 show position
of monocistronic (5’Src-FLuc) and dicistronic (5’Src-RFluc) RNAs respectively as RNA
markers. The 32P-labeled oligonucleotide probe was derived from 3’ end of the FLuc
ORF. Overexposure of the film during autoradiography (for more than a week) did not
show any fragment of the dicistronic mRNA in lane 3.
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(lane 6) and was comparable to that of wild type 5’Src-FLuc RNA. The predicted
structure of this mutant c-Src motif (not shown) by M-Fold program showed significant
similarities in the domains I and II of the wild type structure (Fig. 4.3).

To determine stability of the reporter constructs, we translated
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uncapped mutant and wild type RNAs in HeLa cell-free lysates as described above.
Total RNAs from each reaction were isolated by RNeasy column method and the input
probes were visualized by autoradiography. As shown in Fig. 4.6C (upper panel), the
amounts of full-length mutant RNAs recovered (lanes 2-5) were similar or better than
that of the wild type 5’Src-FLuc (lane 1). The quantity of 18S rRNA (internal control) in
each lane had minor variations (lower panel). This observation suggests that the mutant
RNAs were although present in the lysates, yet these RNAs were unable to support
translation of FLuc due to absence of essential elements in the c-Src sequence motif. The
different band intensities observed for the RNA probes may likely be due to minor
differences in stability and/or loss during purification process. A similar observation was
also made during transfection of three mutant RNAs (D2, D3 and DC) into Huh7 cells.
Although full-length mutant RNA probes were purified from the transfected cells (Fig.
4.6F), only D3 mutant showed efficient synthesis of reporter FLuc (Fig. 4.6E). These
results further suggest that a functional IRES that is represented by the c-Src motif in D3
mutant (Domains I and II, Fig.4.3) was capable of directing translation by capindependent mechanism in cells as well as in the cell-free lysates. Unlike known cellular
IRESs, this IRES requires coding region for its optimal function.
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We carried out kinetic analysis of translation promoted by the wild type and
mutant c-Src motifs in HeLa translation lysates. The time-course experiment presented
in Fig. 4.6 D shows that translation of the 5’Src-FLuc RNA exponentially increased with
time whereas the mutant 5’SrcD2-FLuc was translated inefficiently at all time-points.
During our investigations (Fig. 4.6D and 4.6E), a minor translation was consistently
observed for D2 mutant RNA. It is possible that sequence motifs that form domain I and
translation site in this RNA might have played a role in the residual translation. These
motifs are, however, absent in D1 and DC mutants that are completely incompetent for
translation initiation.

3.5. Assembly of 80S initiation complex on the c-Src IRES in HeLa cell-free
translation lysates is not affected by inhibition of eIF2

Sucrose density gradient analysis was carried out to study assembly of 80S
translation initiation complex on the c-Src IRES. The 32P-labeled uncapped 5’Src-FLuc
RNA or capped FLuc was incubated for 15 min in HeLa cell-free translation lysates
containing 1 mM GMP-PNP, a nonhydrolyzable GTP analogue, which causes
accumulation of 48S complex and inhibition of 80S formation on a capped mRNA
(Pestova et al 1998, Pestova et al 2008). The reaction mixtures were analyzed for
ribosome assembly on the mRNAs by 10%-30% sucrose density gradient centrifugation
method. The initiation complexes in the gradient fractions were determined by
incorporation of the input RNA probe into the ribosomal complexes (Fig. 4.7A). A
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single peak (Peak I, solid line with squares) of ribosomal complex containing the input
RNA probe, 18S and 28S rRNA was obtained for the 5’Src-FLuc RNA (Fig. 4.7B, lane
4). The result clearly established assembly of 80S complex on the c-Src 5’NCR motif,
which was not inhibited by 1 mM GMP-PNP (Fig. 4.7A and 4.7B).

In a similar

translation reaction, we further reduced GTP and ATP concentrations by omitting the
10X reaction buffer from the translation mixture.

This omission caused 10-times

increase in the GMP-PNP to GTP ratio during translation. Interestingly, 80S assembly
on the 5’Src-FLuc mRNA probe occurred (Peak I, broken line with squares; Fig. 4.7B,
lane 5) similar to the standard reaction conditions described above. On the contrary,
when a capped FLuc mRNA probe that lacks the c-Src motif was used in a standard
translation reaction supplemented with 1 mM GMP-PNP, only 48S complex was
obtained as expected (Peak II, solid line with triangles). This conclusion was based on the
observation that peak II lacks 28S RNA, showed lower sedimentation than peak I, and
contains only input RNA probe and 18S rRNA (Fig. 4.7B, lane 7). In addition, the 48S
complex assembly was considerably reduced when cap structure was absent in the FLuc
RNA probe (Peak II, broken line with triangles, Fig 4.7A and Fig. 4.7B, lane 6).

The

GMP-PNP is known to inhibit GTPase function that is required for the assembly of 80S
complex on a capped mRNA. Thus, the observed cap-independent 80S assembly on the
c-Src IRES is most likely to be independent of eIF2 function.
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Figure 4.6. Effect of deletion mutations on the c-Src sequence-controlled translation of
reporter RNAs. A, The organization of in vitro transcribed uncapped wild type reporter
RNA (5’Src-RFluc) and the mutants containing various lengths of deletions (D) in the cSrc sequences are shown; dashed line, extent of deletion. AUG, initiator codon is
underlined. B, The RNAs were translated for 1.5 hr in HeLa lysates in the presence of
[35S]Methionine and the FLuc protein bands were visualized by autoradiography after
SDS-PAGE.
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Figure 4.6 continued. C, Stability of the reporter RNAs in HeLa translation lysates.
The 32P-labeled reporter RNAs (~1x106 dpm) were added to a standard HeLa translation
mixture for 1.5 hr and total RNAs were isolated by Qiagen RNeasy column method. Half
of the eluted RNA samples (20 ul) were subjected to formaldehyde-agarose gel
electrophoresis. The gel was photographed after ethidium bromide staining for detection
of ribosomal RNAs (lower panel), dried and autoradiographed (upper panel). Reporter
RNAs are as indicated for each lane. D, Comparison of the kinetics of translation
between wild type 5’Src-FLuc and a deletion mutant (5’SrcD2-FLuc). The RNAs were
translated in a standard HeLa lysates mixture and FLuc activities were assayed with an
aliquot (2 ul) of the reaction at various time-points. Control, translation lysates without
exogenous RNA.
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Figure 4.6 continued. E, Transfection of uncapped monocistronic c-Src mutant RNAs.
The Huh7 cells (80% confluent in 60 mm culture plates) were transfected in triplicates
with uncapped RNAs as indicated and FLuc activities were assayed 3 hrs post
transfection in the total lysates. F, Relative stability of mutant reporter RNAs in the
transfected cells. The 32P-labeled mutant RNAs (as indicated) were transfected as above.
The total RNAs were isolated and the labeled RNAs were detected by agarose gel
electrophoresis followed by autoradiography of the dried gel (upper panel). Lower panel,
the same gel showing 18S rRNA in each lane.
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In a similar experiment, the assembly of ribosomal complex on a mutant
poliovirus 5’NCR containing FLuc (PVD286-605-FLuc) was compared with the 5’SrcFLuc RNA in the presence of 1 mM GMP-PNP (Figs. 4.7C and 4.7D). The uncapped
5’Src-FLuc RNA showed assembly of 80S in a reproducible manner (Peak I, squares
with solid line; Fig. 4.7D, lane 3). However, the uncapped PVD286-605-FLuc RNA
showed a peak at lower sucrose density (Fig. 4.7C, Peak II, triangles with broken line;
Fig 4.7D, lane 4) and the complexes were spread over a wide range of sucrose density,
most likely due to varying composition of ribonucleoprotein complexes formed with the
mutant PV RNA.

The assembly of 80S on the c-Src IRES was further strengthened by our finding
that purified HeLa 40S ribosomal subunit directly interacts with the c-Src IRES (Fig.
4.8A). The purified 40S subunit was mixed with uncapped 32P-labeled IRES fragment of
the 5’Src-FLuc and bound complex was separated from the free probe by sucrose density
gradient centrifugation. Characterization of the peak fractions revealed the presence of
18S rRNA and the probe in the same peak (inset, lane 1) while the free IRES probe
showed a peak at lower sucrose density.

A non-specific RNA probe of similar length

and nucleotide contents (PVD286-605 5’NCR) failed to form 40S-RNA binary complex
in this assay (Fig. 4.8B and inset lane 2). These results together provide evidence that the
c-Src mRNA contains an IRES element that directly interacts with the 40S ribosomal
subunit and is capable of assembling 80S complex during conditions when eIF-2 function
is significantly compromised.
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3.5. c-Src IRES-mediated translation is enhanced when cap-dependent
translation is inhibited.

The eIF4E protein is a key translation initiation factor that binds the 5’ cap
structure of an mRNA and initiates assembly of 48S pre-initiation complex (Sonenberg
and Hinnebusch 2007).
It has been shown that m7GDP inhibits eIF4E function by occupying its capbinding site. Therefore, cap-dependent translation is efficiently inhibited by the m7GDP
cap analogue (Kentsis et al 2005). The cap-dependent translation of a FLuc RNA which
contains 5’cap and 3’polyA tail at the respective ends of the luciferase ORF but lacks an
IRES (5’Cap-FLuc), was inhibited by m7GDP in a dose-dependent manner in RRL (Fig.
4.9A).

In contrast, the HCV IRES-controlled translation of a reporter FLuc ORF

(5’HCV-FLuc) was stimulated until a threshold concentration (10 ug) of m7 GDP was
reached.

Above this concentration, both cap- as well as HCV IRES-dependent

translations were inhibited. Interestingly, translation of the 5’SrcD3-FLuc RNA (genetic
organization shown in Fig. 4.6A) was considerably enhanced in the presence of m7GDP
as observed for the HCV IRES-mediated translation initiation.
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Figure 4.7 Assembly of translation initiation complexes on the c-Src IRES in HeLa cellfree lysates and analysis by sucrose density gradient centrifugation. A, The translation
mixtures were incubated with 1 mM GMP-PNP on ice-bath for 5 min and in vitro
transcribed 32P-labeled RNAs: 5’Src-FLuc (squares in solid line) or capped FLuc (lacking
IRES, triangles in solid line) or uncapped FLuc (triangles in broken line) were added to
the translation reaction and incubated for 15 min at 30°C. The complexes formed in the
absence of exogenous ATP and GTP on the 5’Src-Fluc probe is shown as squares in
dashed line. The lysates were separated by 10%-30% sucrose density gradient
centrifugation and fractions (250 ul) were collected from the bottom of the tube to
determine RNA contents. B, Total RNAs from the peak fractions (Peak I or Peak II)
were isolated and analyzed by agarose gel electrophoresis. Marker lanes: 1, input 5’SrcFLuc RNA probe; 2, total RNA extracted from HeLa S10 translation lysate showing 18S
and 28S rRNAs; 3, 18S rRNA extracted from purified 40S subunit. The total RNAs
extracted from Peak I (fractions 5 and 6) for 5’Src-Fluc probe are shown in lanes: 4,
standard translation reaction shown as squares in solid line (section A), and 5, translation
reaction deficient in exogenous ATP/GTP (squares in broken line shown in A). RNAs
isolated from Peak II are shown in lanes 6 (triangle, broken line) and 7 (triangle, solid
line).
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Figure 4.7 continued: C, Comparison of ribosomal complex formed at wild type c-Src
IRES and a mutant PV 5’NCR used as scrambled IRES in the presence of 1 mM GMPPNP. The 32P-labeled uncapped 5’Src-Fluc (squares in solid line) or 5’PV(D286-605)FLuc (scrambled IRES, triangles in dashed line) RNAs were used in sucrose gradient
centrifugation analysis as described above. D, The total RNA isolated and resolved by
agarose gel electrophoresis is shown. Lanes 1 and 2, rRNA (as markers) isolated from
lysates and purified 40S subunit respectively; lanes 3 and 4, RNA isolated from Peak I
and Peak II respectively.

129

Figure 4.8. Direct binding of the c-Src IRES with purified HeLa 40S ribosomal subunit.
A, Purified HeLa 40S subunit was mixed with 32P-labeled RNA representing c-Src nt 1383 (solid line) and subjected to sucrose density gradient centrifugation. A separate
sample without 40S was run to locate position of the free probe (broken line) during
sedimentation. Peak fractions were analyzed for RNA contents (inset). Inset, lanes: M,
18S rRNA as marker; 1, RNA extracted from 40S plus probe peak; 2, RNA from free
probe peak.
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Figure 4.8. continued. B, An experiment similar to that described in section A but
repeated with a scrambled IRES [5’PV(D286-605)] as indicated. Inset: lane M, 18S
rRNA; RNA isolated from c-Src IRES probe (lane 1) and scrambled IRES probe (lane 2).
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Next, we examined translation of a capped dicistronic RNA (5’Src-RFLuc, Fig.
4.5A) in RRL in the presence of increasing concentrations of m7GDP. The wild type cSrc IRES-controlled translation of FLuc was initially enhanced in the presence of m7GDP
(5-10 ug) as observed for its monocistronic counterpart, whereas cap-dependent
translation of the upstream renilla luciferase (RLuc) ORF continued to decline with
increasing concentrations of m7GDP (Fig. 4.9B). Although the requirement of inhibitor
concentration to inhibit overall translation was a little higher than that of the
monocistronic RNAs, the stimulation pattern of the c-Src IRES in the presence of
m7GDP was similar for both mono- and dicistronic templates. During several control
experiments , we observed that m7GTP cap analogue also causes stimulation of the c-Src
IRES in HeLa and RRL cell-free translation systems whereas the unmethylated
nucleotides (GTP or GDP) had no effects within the concentration range used in our
studies.

These results together with those described above (Figs. 4.4, 4.6 and 4.7)

established the presence of a functional IRES in the c-Src mRNA that can be activated
when cap-function is absent or significantly inhibited and/or eIF-2 activity is inadequate
in the translation system.

We treated Huh7 cells with 1 uM TG for different time-points (0.5 to 6 hrs) and
monitored the status of eIF2a by Western blot. We observed a considerable increase in
the phosphorylation level of eIF2a within 30 min of TG-treatment, which remained
elevated for 6 hr (Fig. 4.10A, lanes 2-6, upper panel). The total eIF2a level, on the other
hand, was not affected by this treatment (Fig. 4.10A, lower panel). The enhanced eIF2a
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phosphorylation may be considered as an indicator for TG-induced cellular stress and
reduction in global cap-dependent translation in the treated Huh7 cells.

In the

subsequent experiments, Huh7 cells were pre-treated with 1 uM TG for 3 hr before
transfection with the capped 5’Src-RFLuc or RL-HCV1b RNAs while maintaining 1 uM
TG. The RL-HCV1b is similar to the 5’Src-RFLuc except that the translation of FLuc
ORF in the RNA is driven by an HCV IRES. The FLuc and RLuc activities were assayed
in the cytoplasmic fractions 3 hrs post-transfection.

The translation of reporter

luciferases in untreated transfected cells (control) were considered as 100% and
compared to that of DMSO- or DMSO-TG- treated cells (Fig. 4.10B).

Both the cap-

dependent and IRES-dependent (HCV or c-Src) translation was not affected by DMSO
treatment of the cells. In contrast, the cap-dependent translation of RLuc was
dramatically reduced for both the RNAs due to DMSO-TG treatment of the cells. In
these cells, however, the c-Src or HCV IRES-controlled translation of FLuc was
moderately enhanced. These results together complement our findings that the c-Src
level in Huh7 cells is modestly enhanced or maintained to steady level under varying
cellular stress conditions that are unfavorable for cap-dependent translation. This effect
is likely to occur due to increase in the c-Src IRES activities.

4. Discussion

An overwhelming majority of reports including polysome-profiling data strongly
advocate for IRES-dependent translation initiation of a subset of cellular mRNAs during
cell division, apoptosis, cellular stress, and viral infections where cap-dependent
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translation initiation is compromised (Spriggs et al 2008). Unlike known cellular IRESs,
the c-Src IRES demonstrated here exhibits many unique attributes that are analogous to
the characteristics of HCV-like IRESs. To identify an IRES function in viral and cellular
mRNAs, mono- and di- cistronic RNA-expressing plasmids have been extensively used
during transfection studies. This approach, however, has been a subject of criticism due
to expression via cryptic promoters, and faulty transcription and splicing of the reporter
constructs (Kozak 2007). To avoid spurious results generated by this method, we have
used only in vitro transcribed capped and uncapped reporter RNAs for cell-free
translation assays, transfection studies, and sucrose density gradient analyses.

The

transcription reactions were digested with DNase I prior to purification and checked by
agarose gel electrophoresis for the absence of DNA contamination in the final RNA
preparations. Furthermore, the reporter RNA transcription is under the control of T7
promoter and transcription of the RNA from plasmid DNA contamination is not possible
in any of the system used here.

We also demonstrated that wild type and mutant c-Src motif containing reporter
RNAs were intact during various translation assays. These measures permitted us to
present reliable data for the identification of c-Src IRES.

We established here that the c-Src IRES-controlled translation can be stimulated
similar to the HCV IRES when eIF4E function is blocked (Fig. 4.9). The initiation factor
eIF4E has been shown to be a negative modulator of the IRES-mediated translation, and
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Figure 4.9. Stimulation of the c-Src IRES-controlled mRNA translation when eIF4E
function is inhibited. A, Capped RNAs: 5’Src-FLuc (triangle), and FLuc (5’Cap-FLuc,
circle) or uncapped 5’HCV-FLuc (square) RNAs were translated in triplicate in the
presence of increasing amounts of m7GDP in RRL for 1 hr, and one-tenth of each
reaction mixture was assayed for FLuc activity. Average FLuc activity of three reactions
is shown for each m7GDP concentration. The FLuc activity in samples without m7GDP
was considered as 100% translation and compared with those containing the cap analogue
(inhibitor). Similar translation reactions were carried out twice to confirm the results. B,
Translation of a capped dual luciferase RNA construct (5’Src-RFLuc) in RRL in the
presence of increasing amounts of m7GDP as described above. Relative cap-dependent
translation of renilla luciferase (RLuc) and c-Src IRES-dependent FLuc synthesis are
shown. Each translation mixture was carried out in triplicate. The results were
confirmed by three independent experiments.
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translation of IRES-containing RNAs is accelerated when eIF4E availability is reduced
(Svitkin et al 2005). This is likely attributed to a decrease in eIF4F complex formation
that may be accompanied by an increased availability of eIF4G/eIF4A or eIF4A RNA
helicase or other initiation factors. Based on these observations, we believe that a direct
binding of m7GDP to eIF-4E in our assay may lead to increased availability of translation
factors that are required for efficient activities of the HCV or c-Src IRESs.

Our in vitro studies that defined presence of an IRES in the c-Src mRNA were
further corroborated by the results of transfection of mono- and dicistronic reporter RNAs
into hepatoma-derived cells and induction of cellular stress in the transfected cells.
Uncapped reporter RNAs containing nt 1-383 of c-Src mRNA at their 5’ends were
efficiently translated in two cell-free translation systems (RRL and HeLa lysates) and in
Huh7 cells.

Our genetic analysis shows that nt 200-383 of the c-Src mRNA, which

harbors initiator AUG (at nt 351), plays pivotal role in promoting cap-independent
translation.

An extensive analysis of the secondary and/or possible higher-order

structures within this region is, however, needed for accurate understanding of its role in
loading productive initiation complex. We found that the c-Src IRES promotes assembly
of stable 80S complexes in the absence of cap structure and in the presence of 1mM
GMP-PNP.

Under similar conditions, however, only 48S complex can be trapped on a

capped reporter RNA lacking a 5’NCR or contains a scrambled IRES.
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Figure 4.10. c-Src IRES-controlled translation is not inhibited during cellular stress. A,
Phosphorylation of eIF2a by thapsigargin (TG) treatment. The cytoplasmic lysates (40
ug) from Huh7 cells that were treated with 1 uM TG for 0.5, 1, 2, 4 and 6 hrs (lanes 2-6)
were subjected to Western blot analysis using anti-[Phospho-eIF2α(Ser51)] antibody
(Cell Signaling, upper panel) and anti-eIF2a antibodies (Sigma, lower panel). Lane 1, 0
min treatment. B, Huh7 cells in triplicate were treated with DMSO alone or 1 uM
thapsigargin dissolved in DMSO (DMSO-TG) for 3 hrs followed by transfection with in
vitro transcribed capped 5’Src-RFLuc RNA (solid black bar) or RL-HCV1b (solid gray
bar). The upstream RLuc in RL-HCV1b RNA is translated by cap-dependent mechanism
whereas HCV IRES mediates downstream FLuc translation. The cytoplasmic lysates
were assayed for FLuc (IRES-dependent translation) and RLuc (cap-dependent
translation) activities 3 hours post-transfection. The activities of FLuc and RLuc in
untreated (control) samples were considered as 100% and compared with the solvent
alone (DMSO) or TG-treated cells.
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Furthermore, similar to the HCV-like IRESs, a direct binding of purified HeLa
40S with the c-Src nt 1-383 was detected in the absence of initiation factors. These
evidence together strongly support existence of a physiologically relevant IRES element
at the 5’ end of c-Src mRNA. The c-Src IRES appears to be functionally similar to the
HCV IRES as both IRES elements directly interact with the purified 40S subunit, require
coding region for their functions, promote eIF2-independent assembly of 80S complex
(Figs. 4.4, 4.6 and 4.7) (Pestova et al 2008, Reynolds et al 1995, Robert et al 2006), and
are stimulated when eIF4E or eIF2a function is impaired (Figs. 4.9 and 4.10). Therefore,
our studies reported here present several unique attributes of a cellular IRES that have
been demonstrated only for HCV-like IRESs.

The sucrose gradient analyses further provided insights into the mechanism of
ribosome assembly on the c-Src IRES. The nonhydrolyzable GTP analogue, GMP-PNP,
blocks eIF2-dependent initiation pathway at the 48S complex stage (Pestova et al 1998,
Pisarev et al 2007). This effect was clearly evident for the cap-dependent translation
initiation of the FLuc mRNA in HeLa cell-free lysates in which the 48S complex was
trapped by 1mM GMP-PNP treatment (Fig. 4.7). Thus, the GMP-PNP concentration
used here during translation initiation assembly was sufficient to block 80S assembly by
cap-dependent initiation mechanism in the translation mixture.

In sharp contrast,

assembly of 80S complex took place on the c-Src IRES in the presence of GMP-PNP or
in a reaction mixture containing the analogue but was also deficient in exogenously
added ATP and GTP. Generally, 60S subunit joins the 48S complex to form 80S only
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after eIF5-induced GTP hydrolysis and dissociation of eIF2.GDP complex (Terenin et al
2008). This step is preceded by ATP-dependent scanning by the 48S complex to locate
AUG codon (Sonenberg and Hinnebusch 2007). From the data presented here, c-Src
IRES appears to evade both of the critical energy-dependent steps that are needed for the
80S assembly by cap-dependent mechanism. Because the c-Src IRES directly binds 40S
subunit (Fig. 4.8) and the structural motifs from flanking regions of the initiator AUG are
required for efficient function of the c-Src IRES (Fig. 4.6), it is highly likely that the 48S
complex formed at this element may not require energy-dependent scanning for the
initiator AUG. This notion is supported by the genetic analysis of the c-Src IRES. A 19
nt-deletion at translation site in 5’Src-D1-FLuc RNA resulted in complete impairment of
the IRES function in spite of the presence of upstream AUG147 and AUG179. Recently,
the HCV IRES was shown to switch from classical eIF2-dependent initiation to eIF2independent pathway under cellular stress that favors inactivation of eIF2 due to
phosphorylation of its a subunit. This alternative pathway was further shown to require
only eIF3 and eIF5B (an analogue of bacterial IF2) for Met-tRNAiMet delivery at the P
site. Based on these observations, it was proposed that the 80S assembly on the HCV
IRES is analogous to bacterial-like mode of translation initiation (Terenin et al 2008). In
this context, the c-Src IRES appears to follow HCV IRES-like mode of translation
initiation when the GTPase function of the ternary complex is blocked. This conclusion
is further supported by RNA transfection studies in which thapsigargin-led induction of
cellular stress in Huh7 cells failed to inhibit the c-Src IRES in spite of increased Ser51
phosphorylation of eIF2a as compared to the normal (unstressed) cells (Fig. 4.10).
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The studies presented here demonstrate significant resistance of the c-Src IRES
activities to reduced level of ternary complex (TC) and eIF-2a phosphorylation. In
contrast to the eIF2-dependent initiation pathway in which the eIF-2 complex delivers
Met-tRNAi to 40S subunits in a GTP-dependent manner, the eIF2A has been shown to
deliver the Met-tRNAi to 40S subunits by AUG-dependent and GTP-independent
mechanism (Robert et al 2006, Zoll et al 2002). In addition, a number of RNA-binding
proteins have been shown to stabilize IRES structure and/or promote ribosomal complex
assembly (Ali and Siddiqui 1997, Wang et al 1995).

A comprehensive analysis is

needed to ascertain whether these factors contribute to the reduced TC-dependence of the
c-Src IRES.

In the cells, stress and serum-deprivation causes inhibition of PI3K/AKT/mTOR
pathway-dependent phosphorylation of eIF4E-BP. The unphosphorylated protein forms a
tight complex with eIF4E and prevents its binding to eIF4G and the cap structure
(Gingras et al 1999). Similarly, hypophosphorylation of eIF4E that is controlled by RasMAPK pathway also reduces its cap-binding ability. Both of these events culminate into
suppression of global cap-dependent translation. In addition, phosphorylation of eIF2a
by cellular kinases (e.g. PKR, PERK, HR1 and GCN2) in response to various cellular
stress and viral infections leads to reduction in the level of ternary complex (eIF2-GTPMet-tRNAiMet) due to inhibition of guanine nucleotide exchange factor (GEF) activity
(Fernandez et al 2002).

Our investigations revealed that 80S assembly on the c-Src

IRES occurs when function of eIF2 and eIF4E are inhibited. Therefore, it is possible that
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the c-Src mRNA can easily escape from tight regulation of both of these translation
initiation factors, which may ultimately lead to continued c-Src protein synthesis during
adverse conditions (e.g. ER stress and starvation). Enhanced c-Src level has been shown
to correlate with its activated state in hepatocellular carcinoma (Ito et al 2001). Activated
c-Src is known to induce phosphorylation of 4E-BP1 via PI3K/mTOR and eIF4E via
Ras/Raf/ERK pathway, both of which favor cell survival and proliferation (Karni et al
2005, Vojtechova et al 2008). Thus, the c-Src IRES controlled translation provides an
important recovery mechanism from translational blockade during cellular stress.

It has been shown that the cap-dependent translation of c-Src mRNA is regulated
by elements located in its long 3’NCR through interaction with hnRNP K (Naarmann et
al 2008). It would be interesting to investigate if hnRNP K or miRNAs can affect the cSrc IRES-controlled translation through the 3’NCR interactions. Both transcripts of the
c-Src gene (Type-1A and Type-1a, Fig.4.1A) contain conserved sequences that constitute
most part of the IRES element. However, the extreme 5’ ends in these mRNAs are
dissimilar in length and nucleotide composition. It is not known if these sequences play
any role in regulating the c-Src translation.

c-Src is an important player in signal transduction pathways that control
oncogenesis, cell-proliferation and metastasis (Alvarez et al 2006, Bjorge et al 2000, Finn
2008, Fizazi 2007). The emerging strategies for treatment of breast, lung, prostate, skin
and other cancers are focused on the inhibition of c-Src activities (Giaccone and Zucali
2008, Ma and Adjei 2009, Serrels et al 2009, Sulkowski 2008) but not the enhanced
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supply of c-Src in the tumor cells.

Many of the small molecules that target c-Src

activities also inhibit other protein kinases and/or show high degree of cytotoxicity (Ma
and Adjei 2009). Adaptation for growth during cellular stress is a hallmark feature of
many cancer cells and c-Src has been shown to play very important role during this
process (Yamamoto et al 2006). Our report presents c-Src IRES as a new therapeutic
target for treatment of cancer. Because the c-Src IRES is located downstream of the cap
structure in the mRNA, interference with the IRES structure and/or function will likely
result in the inhibition of cap-dependent as well as IRES-dependent c-Src synthesis. This
strategy will prevent unabated c-Src supply in the cancer cells, and hence is likely to
reduce the chances of cancer cell survival.

5. Chapter Summary

Overexpression and activation of c-Src protein have been linked to the
development of a wide variety of cancers.

The molecular mechanism(s) of c-Src

overexpression in cancer cells is not clear. We report here an internal ribosome entry site
(IRES) in the c-Src mRNA that is constituted by both 5’ noncoding and coding regions.
The inhibition of cap-dependent translation by m7 GDP in cell-free translation system or
induction of ER stress in hepatoma-derived cells resulted in stimulation of the c-Src IRES
activities.

Sucrose density gradient analyses revealed formation of a stable binary

complex between the c-Src IRES and purified HeLa 40S ribosomal subunit in the
absence of initiation factors. We further demonstrate eIF2-independent assembly of 80S
initiation complex on the c-Src IRES. These features of the c-Src IRES appear to be
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reminiscent to that of hepatitis C virus-like IRESs and translation initiation in
prokaryotes. Transfection studies and genetic analysis revealed that the c-Src IRES
permitted initiation at the authentic AUG351 which is also used for conventional
translation initiation of the c-Src mRNA.

Our studies unveiled a novel regulatory

mechanism of c-Src synthesis mediated by an IRES element, which exhibits enhanced
activity during cellular stress, and is likely to cause c-Src overexpression during
oncogenesis and metastasis.
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Chapter Five: Summary

Hepatitis C virus (HCV) is a positive strand RNA virus and has been classified as
a hepacivirus of the family Flaviviridae. More than 180 million people (>4 million in
USA alone) have already been infected and HCV-related liver diseases are on rising trend
globally due to addition of 3-4 million new cases per year. The HCV infection causes
chronic hepatitis (70%-80%) that may lead to the development of cirrhosis, steatosis and
hepatocellular carcinoma (HCC). In spite of aggressive efforts during last 15 years by
scientists and pharmaceutical companies, cure for the infection as well as vaccine against
the virus remained elusive. The current standard-of-care treatments (e.g. interferon with
ribavirin for 24-48 weeks) alone or in combination with the HCV-specific drugs (e.g.
telaprevir and boceprevir) have shown partial success. The HCV-related HCC are
believed to contain a subpopulation of poorly differentiated cancer stem-like cells
(CSCs), which exhibit a strong potential to initiate tumor formation and resistance to antineoplastic drugs. Keeping in view of the above described problems, my thesis work was
focused on three major specific aims: 1) To investigate if HCV-expressing cells undergo
phenotypic changes and exhibit enhanced expression of oncogenes (e.g. c-Src) and
putative cancer stem cell markers, 2) To investigate possible mechanism of the HCVinduced hepatocarcinogenesis, 3) To develop novel means for targeting marker (s) that
control abundance of the HCV genome.
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In these studies, we demonstrate that expression of HCV subgenomic replicon in
cultured cells results in acquisition of CSCs traits.

These traits include enhanced

expression of DCAMKL-1, Lgr5, CD133 and c-Myc in conjunction with long-term
maintenance of pluripotency factors. We also show that HCV replication is severely
impaired by siRNA-led depletion of the microtubule-associated putative stem cell
marker, DCAMKL-1. The DCAMKL-1-positive cells isolated by fluorescence activated
cell-sorting (FACS) form spheroids in matrigel.

We further demonstrate that HCV

replicon-expressing cells initiate tumors in nude mice. The resulting tumors exhibit
characteristics of HCCs that are originated from hepatic progenitor-like cells and are
phenotypically distinct from the tumors initiated by parent cells lacking the replicon.
This phenotype expresses high-levels of
markers.

HCV-induced activation of

-fetoprotein, cytokeratin-19 and pluripotency
-catenin, c-Myc, and c-Src indicates the

aggressive nature of the tumor. These results collectively suggest that HCV exhibits
ability to induce reprogramming and/or retrodifferentiation of the host cells.

DCAMKL1 is a putative stem cell/CSC protein that affects ‘dynamic instability’ of
microtubule filaments (MTFs), a process required for movement of HCV replication
complexes (RCs), cellular transport and survival.

Our findings that this protein is

overexpressed in HCV replicon model and DCAMKL-1 antagonist leads to specific
reduction in the HCV RNA and protein levels are novel. Subsequent studies showed that
the cholesterol-lowering drug, fluvastatin (FLV, inhibitor of HMG CoA reductase), induce
MTF bundling specifically in the HCV-expressing cells and hepatoma cells but not in the
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normal human hepatocytes. However, pravastatin failed to show such effects under similar
conditions. The fluvastatin effect on MTFs was accompanied by changes in localization of
the RCs and DCAMKL1 with the MTFs. DCAMKL1 RNA level was also reduced to a
considerable extent by the FLV treatment.

Because overexpression and activation of c-Src protein have been linked to the
development of a wide variety of cancers including HCC, we investigated molecular
mechanism(s) of c-Src overexpression in hepatoma cell lines. The studies revealed a
novel type of internal ribosome entry site (IRES) in the c-Src mRNA that is constituted
by both 5’ noncoding and coding regions. The inhibition of cap-dependent translation by
m7GDP in cell-free translation system or induction of ER stress in hepatoma-derived cells
resulted in stimulation of the c-Src IRES activities. Sucrose density gradient analyses
revealed formation of a stable binary complex between the c-Src IRES and purified HeLa
40S ribosomal subunit in the absence of initiation factors. We further demonstrate eIF2independent assembly of 80S initiation complex on the c-Src IRES. These features of the
c-Src IRES appear to be reminiscent to that of hepatitis C virus-like IRESs and
translation initiation in prokaryotes. Transfection studies and genetic analysis revealed
that the c-Src IRES permitted initiation at the authentic AUG351 which is also used for
conventional translation initiation of the c-Src mRNA. Thus, these results unveiled a
novel regulatory mechanism of c-Src synthesis mediated by an IRES element, which
exhibits enhanced activity during cellular stress, and is likely to cause c-Src
overexpression during HCV-induces liver tumorigenesis.
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In conclusion, the studies presented here revealed a novel HCV-(DCAMKL-1)MTF-CSCs axis that might be responsible for the HCV RNA abundance in the infected
cells and HCV-induced hepatocarcinogenesis. The putative stem cell marker, DCAMKL1, represents a novel cellular target for combating HCV and liver cancer. We showed
that its role in the HCV replication could be controlled by a combination of antiDCAMKL-1 agent with FDA-approved fluvastatin and/or HCV-specific drugs. The
concept of a ‘virus-induced stem cell traits’ can also be extrapolated to study diseases
caused by other RNA viruses.
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Appendices
Appendix 1

Indirect immunofluorescence of stem cell and cancer related markers as indicated
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Appendix 2

Expression and co-expression (indicated with arrows) pattern of cytokeratin 19 (purple)
and a-fetoprotein (brown) in GS5-derived (A) or Huh7.5-derived (B) tumor xenografts.
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Appendix 3

DCAMKL1 staining results of the human liver tissue array. The arrays were processed
for immunohositochemical staining. (A) Examples of DCAMKL1 intensities in different
liver diseases. (B) Evaluation of DCAMKl1 intensities in different cell populations
using the array on a arbitrary scale of 0-3.
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Appendix 4

Translation of capped dicistronic RNA controls in Huh7 cells during transfection assay.
The Huh7 cultured cells (80% confluency, 50 mm dish) were transfected with 10 ug
capped RL-HCV1b or a dual luciferase vector lacking an IRES between upstream RLuc
and downstream FLuc ORFs. Renilla and firefly luciferase activities were assayed in the
cytoplasmic fractions as described for Fig. 4.4. The cap-dependent Rluc and HCV IRESdependent FLuc for RL-HCV1b are shown.
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Appendix 5

Immunoflorescence detection of FLuc expressed by c-Src IRES-controlled translation of
5’Src-FLuc RNA in Huh7 cells. A, The amino acid sequence encoded by the coding
region in the c-Src IRES is shown. HCV IRES containing FLuc (5’HCV-FLuc) lacks
this sequence. B, Huh7 cells were transfected with uncapped 5’Src-Fluc or 5’HCV-FLuc
RNAs. Indirect immunoflorescence staining for FLuc (green) was carried out with
monoclonal FLuc antibody 48 hr post-transfection. Dapi, nuclear staining with bisbenzimide.
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